Actions of heparin in the atherosclerotic process

Pharmacological Reviews

Volumn 48, Issue 2, 1996, Pages 327-352

  Engelberg, Hyman ^a  

^a California Arteriosclerosis Res F   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; OXYGEN RADICAL;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; HEPARINIZATION; HUMAN; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANIMALS; ANOXIA; ARTERIOSCLEROSIS; COMPLEMENT ACTIVATION; ENDOTHELINS; ENDOTHELIUM, VASCULAR; FIBRINOGEN; GLYCOSYLATION; HEPARIN; HUMANS; LIPOPROTEIN LIPASE; LIPOPROTEINS; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM;

EID: 0029973399     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (462)

1. ABRAHAM, E., BURSTEN, S., SHENKER, R., ALBEE, J., TUDER, R., WOODSON, P., ET AL.: Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury after hemorrhage in mice. J. Exp. Med. 181: 569-575, 1995.
2. ABRAHAMSON, T., BRANDT, V., MARKLUND, S. L., AND SHOQUIST, P.-O.: Vascular bound recombinant extracellular superoxide dismutase type C protects against the detrimental effects of superoxide radicals on endothelium-dependent arterial relaxation. Circ. Res. 70: 264-271, 1992.
3. ADAMS, D. D., AND HAMILTON, T. A.: Macrophages as destructive cells in host defense. In Inflammation-Basic Principles and Clinical Correlates, ed. by J. I. Gallin, I. M. Goldstein, and R. Snyderman, Raven Press, New York, pp. 637-662, 1992.
4. ADAMS, D. H., AND SHAW, S.: Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet. 343: 831-836, 1994.
5. AGWAR, D. E., MCPHAIL, L. C., SOZZANI, S., BASS, D. A., AND MCCALL, C. E.: Phosphatidic acid as a second messenger in human polymorphonuclear leucocytes: effects of NADPH oxidase. J. Clin. Invest. 88: 531-539, 1991.
6. AMBROSIO, G., ORIENTE, A., NAPOLI, C., PALUMBO, G., CHIARIELLO, P., MARONE, G., ET AL.: Oxygen radicals inhibit plasma acetylhydrolase, the enzyme that catabolizes platelet activating factor. J. Clin. Invest. 93: 2351-2356, 1994.
7. ANDERSON, T. J., GERHARD, M. D., MEREDITH, I. T., CHARBONNEAU, F., DELAGRANGE, D., CREAGER, M. A., SELWYN, A. P., AND GRANZ, P.: Systemic nature of endothelial dysfunction in atherosclerosis. Am. J. Cardiol. 75: 71B-74B, 1995.
8. ANFINSEN, C. B., BOYLE, E., AND BROWN, R.: The role of heparin in lipoprotein metabolism. Science. 115: 583-586, 1952.
9. ARANJA, F. B., BARBOSA, D. S., HAIN, C. Y., MARANHAO, R. C., AND ABDALLA, D. S. P.: Evaluation of oxidative stress in patients with hyperlipidemia. Atherosclerosis. 117: 61-71, 1995.
10. ARNDT, H., RUSSELL, J. B., KUROSE, I., KUBES, P., AND GRANGER, D. N.: Mediators of leukocyte adhesion in rat mesenteric venules elicited by inhibition of nitric oxide synthesis. Gastroenterology. 105: 675-680, 1993.
11. ASGHAR, S. S.: Membrane regulators of complement activation and their aberrant expression in disease. Lab. Invest. 72: 254-267, 1995.
12. AU, Y. P. T., MORRIS, D. R., AND CLOWES, A. W.: Heparin inhibits the transcription of tissue plasminogen activator and interstitial collagenase in part by suppressing the expression of jun-B in baboon vascular smooth muscle cells (abstract). FASEB J. 7: 1829, 1993.
13. AUVERX, J. H., BABIRAK, S. P., FUJIMOTO, W. Y., IVERIUS, R. H., AND BRUNZELL, J. D.: Defective enzyme protein in lipoprotein lipase deficiency. Eur. J. Clin. Invest. 19: 433-437, 1989.
14. AVIEZAR, D., AND YAYON, A.: Heparin-dependent binding and autophosphorylation of epidermal growth factor (EGF) by heparin-binding EGF-like growth factor but not by EGF. Proc. Natl. Acad. Sci. USA 91: 12173-12177, 1994.
15. AVIRAM, M.: LDL-platelet interaction under oxidative stress induces macrophage foam cell formation. Thromb. Haemostasis. 74: 560-564, 1995.
16. AVIRAM, M., AND MAOR, I.: Phospholipase D-modified LDL is taken up by macrophages at an increased rate: a possible role for phosphatidic acid. J. Clin. Invest. 91: 1942-1952, 1993.
17. 2 in vascular smooth muscle cells. Circ. Res. 77: 29-36, 1995.
18. BAILEY, W. L., LAFLEUR, D. W., FORRESTER, J. S., FAGIN, J. A., AND SHARIFI, B. G.: Stimulation of rat vascular smooth muscle cell glycosaminoglycan production by angiotensin II. Atherosclerosis. 111: 55-64, 1994.
19. BAILEY, A. J., SIMS, T. J., AVERY, N. C., AND HALLIGAN, E. P.: Non-enzymic glycation of fibrous collagen: reaction products of glucose and ribose. Biochem. J. 305: 385-390, 1995.
20. BALDWIN III, W. M., PRUITT, S. K., BRAUER, R. B., DAHA, M. R., AND SANFILIPPO, F.: Complement in organ transplantation: contribution to inflammation injury and rejection. Transplantion. 59: 797-808, 1995.
21. BALLA, G., VERCELLOTTI, G. M., EATON, J. W., AND JACOBS, H. S.: Iron loading of endothelial cells augments oxidant damage. J. Lab. Clin. Med. 116: 546-554, 1990.
22. BAME, K. J.: Release of heparan sulfate glycosaminoglycans from proteoglycans in Chinese hamster ovary cells does not require proteolysis of the core protein. J. Biol. Chem. 268: 56-64, 1993.
23. BANNON, P. G., KIM, M.-J., DEAN, R. T., AND JAWES, J.: Augmentation of vascular endothelial barrier function by heparin and low molecular weight heparin. Thromb. Haemostasis. 73: 706-712, 1995.
24. BARKER, S. G. E., TALBERT, A., COTTAM, S., BASKERVILLE, P. A., AND MARTIN, J. F.: Arterial intimai hyperplasia after occlusion of the adventitial vasa vasorum in the pig. Arterioscler. Thromb. 13: 70-77, 1993.
25. BARNES, J. L., AND VENKATOCHALAM, M. A.: Enhancement of glomerular immune complex deposition by a circulating polycation. J. Exp. Med. 160: 286-293, 1984.
26. BARTLETT, M. R., BLOWDEN, W. B., AND PARISH, C. R.: Differential effects of the anti-inflammatory compounds heparin, mannose-6-phosphate, and castano-spermine on degradation of the vascular basement membrane by leukocytes, endothelial cells and platelets. J. Leuk. Biol. 57: 207-13, 1995.
27. BEEKHUIZEN, H., AND VON FURTH, R.: Monocyte adherence to vascular endothelium. J. Leukocyte Biol. 54: 363-378, 1993.
28. BEG, P., MENG, M. S., SKARLATOS, S. L., PREVIATO, L., BRUNZELL, J. D., BREWER, JR., H. G., AND FOJO, S. S.: Lipoprotein lipase Bethesda: a single amino acid substitution leads to abnormal heparin binding and to loss of enzyme activity. Proc. Natl. Acad. Sci. USA 87: 3474-3478, 1990.
29. BENNETT, M. B., ANGLIN, S., MCEVAN, J. R., JAGOC, R., NEWBY, A. C., AND EVAN, G. I.: Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J. Clin. Invest. 93: 820-828, 1994.
30. BERENSON, G. S., RADHAKRISHNAMURTHY, B., SRINIVASUN, S. R., VIJAYAGAPOL, P., DALFERES, JR., E. R., AND SHARMA, C.: Recent advances in molecular pathology: carbohydrate-protein macromolecules and arterial wall integrity - a role in atherogenesis. Exp. Mol. Pathol. 41: 267-287, 1984.
31. BERLINER, J. A., AND HABERLAND, M. E.: The role of oxidized LDL in atherogenesis. Curr. Opin. Lipidol. 4: 373-381, 1993.
32. BERMAN, R. S., AND MARTIN, W.: Arterial endothelial barrier dysfunction: actions of homocysteine and the hypoxanthine-xanthine oxidase free radical generating system. Br. J. Pharmacol. 108: 920-926, 1993.
33. BERNFIELD, M., KOKENYESI, R., KATO, M., HINKES, M. T., SPRING, J., GALLO, R. L., ET AL.: Annu. Rev. Cell Biol. 8: 363-393, 1992.
34. BJORNHEDIN, T., AND BONDGERS, G.: Oxygen consumption in aortic tissue from rabbits with diet-induced atherosclerosis. Arteriosclerosis. 7: 238-247, 1987.
35. BLOOM, A. D.: Endothelial cell damage and homocysteine. Atherosclerosis. 94: 89-91, 1992.
36. BORNFELDT, K. E., RAINES, E. W., NAKANO, T., GRAVES, L. M., KREBS, E. G., AND ROSS, R.: IGF-1 and PDGF-BB induce directed migration of human arterial smooth muscle cells via signalling pathways that are distinct from those of proliferation. J. Clin. Invest. 93: 1266-1274, 1994.
37. BOULANGER, C. M., TANNER, F. C., BEA, M. L., HAHN, A. W. A., WERNER, A., AND LUSCHER, T. F.: Oxidized low density lipoproteines induce m-RNA expression and release of endothelin from human and porcine endothelium. Circ. Res. 70: 1191-1197, 1992.
38. BRADLEY, W. A., BOOYSE, F. M., AND GIANTURCO, S. H.: Fibrinolytic and thrombotic factors in atherosclerosis and ischemic heart disease: the influence of triglyceride-rich lipoproteins. Atherosclerosis. 110(suppl.): 531-539, 1994.
39. BRESTEL, E. P., AND KOES, M. T.: Heparin inhibits the quasi-lipoxygenase activity of hemoglobin toward linoleic acid by oxidant scavenging. Prostaglandins Leukotrienes Essent. Fatty Acids. 36: 21-24, 1989.
40. BRESTEL, E. P., AND MCCLAIN, E. J.: A mechanism for inhibition of luminol-dependent neutrophil chemiluminescence by heparin. J. Immunol. 131: 2515-2519, 1983.
41. BROWN, Z., GERRITSEN, M. E., CARLEY, W. W., STRIETER, R. M., KUNKEL, S. L., AND WESTWICK, J.: Chemokine gene expression and secretion by cytokine-activated human microvascular EC. Am. J. Pathol. 145: 913-921, 1994.
42. BROWN, M. S., AND GOLDSTEIN, J. L.: Kochs postulates for cholesterol. Cell 71: 187-188, 1992.
43. BROWNLEE, M.: Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 46: 223-234, 1995.
44. BUCALA, R., MITCHELL, R., ARNOLD, K., INNERARITY, T., VLASSARA, H., AND CERAMI, A.: Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the LDL receptor. J. Biol. Chem. 270: 10828-10832, 1995.
45. BURSTEN, S. L., HARRIS, W. E., BOMSZTYK, K., AND LOVETT, D.: Interleukin-1 rapidly stimulates lysophosphatidate acyltransferase and phosphatidate phosphohydrolase activities in human mesangial cells. J. Biol. Chem. 266: 20732-20743, 1991.
46. BUSCH, S. J., MARTIN, G. A., BARNHART, R. L., AND JACKSON, R. L.: Heparin induces the expression of hepatic triglyceride lipase in a human hepatoma cell line. J. Biol. Chem. 264: 9527-9532, 1989.
47. BUTLER, A. J., EAGLETON, M. J., WANG, D., HOWELL, R. L., STROUCH, A. R., KHASGIEVALA, V., AND SMITH, H. C.: Induction of the proliferative phenotype in differentiated myogenic cells by hypoxia. J. Biol. Chem. 266: 18250-18258, 1991.
48. CAMBIEN, F., POIRIER, O., LECER, L., EVANS, A., CAMBOU, J. P., AND ARVELLER, D.: Deletion polymorphism in the gene for angiotensin converting enzyme is a potential risk factor for myocardial infarct. Nature (Lond.) 359: 641-644, 1992.
49. CAMEJO, G., FAGER, G., ROSENGREN, B., HURT-CAMEJO, E., AND BONDGERS, G.: Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. J. Biol. Chem. 268: 14131-14137, 1993.
50. CAMEJO, G., OLOFSSON, S-O., LOPEZ, F., CARLSSON, P., AND BONDGERS, G.: Identification of apo-B-100 segments mediating the interaction of low density lipoproteins with arterial proteoglycans. Arteriosclerosis. 8: 368-377, 1988.
51. CAMERON, N. E., AND COTTER, M. A.: Neurovascular dysfunction in diabetic rats: potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J. Clin. Invest. 96: 1159-1163, 1995.
52. CAMPBELL, J. H., AND CAMPBELL, G. R.: Endothelial cell influences on vascular smooth muscle cell phenotype. Am. Rev. Physiol. 48: 295-306, 1986.
53. CAMPBELL, J. H., AND CAMPBELL, G. R.: The macrophage as an initiator of atherosclerosis. Clin. Exp. Pharmacol. Physiol. 18: 81-84, 1991.
54. CAMUSSI, G., TETTA, C., SEGOLINI, G., CODA, R., AND VERCELLONI, A.: Localization of neutrophil cationic proteins and loss of anionic charges in glomeruli of patients with systemic lupus erythematosus glomerulonephritis. Clin. Immunol. Immunopathol. 24: 299-314, 1982.
55. CAPLICE, M., WEST, M. J., CAMPBELL, G. R., AND CAMPBELL, J.: Inhibition of human vascular smooth muscle cell growth bv heparin. Lancet. 344: 97-98, 1994.
56. CARR, M. W., ROTH, S. J., LUTHER, E., ROSE, S. S., AND SPRINGER, T. A.: Monocyte chemoattractant protein-1 acts as a T-lymphocyte chemoattractant. Proc. Natl. Acad. Sci. USA 91: 3652-3656, 1994.
57. CATERINA, R. D., LIBBY, P., AND PENG, H-B.: Nitric oxide decreases cytokine-induced endothelial activation: NO selectively reduces endothelial expression of adhesion molecules and pro-inflammatory cytokines. J. Clin. Invest. 96: 60-68, 1995.
58. CAVARI, S., STRAMOCCIA, L., AND VANNUCCHI, S.: Endogenous heparinase-sensitive anticoagulant activity in human plasma. Thromb. Res. 67: 157-165, 1992.
59. CELI, A., PELLEGRINI, G., LORENZET, R., DEBLASI, A., READY, N., FURIE, B. C., ET AL.: P-selectin induces the expression of tissue factor on monocytes. Proc. Natl. Acad. Sci. USA 91: 8767-8771, 1994.
60. CELERMAIER, D. S.: Detecting and treating early atherosclerosis. Med. J. Aust. 162: 172-173, 1995.
61. CELERMAIER, D. S., SORENSON, K. E., GOOCH, V. M., SPIEGELHALTER, D. J., MILLER, O. J., SULLIVAN, I. D., LLOYD, J. K., AND DEANFIELD, J. E.: Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 340: 1111-1115, 1992.
62. CERILLI, J., BRASILE, L., AND KARMODY, A.: Role of the vascular endothelial cell antigen system in the etiology of atherosclerosis. Ann. Surg. 202: 329-334, 1985.
63. CERLETTI, C., RAJTAR, G., MARCHI, E., AND DEGAETANO, G.: Interaction between glycosaminoglycans, platelets and leukocytes. Semin. Thromb. Hemostasis. 20: 245-253, 1994.
64. CIAFRA, S. A., D'ARMIENTI, F. P., DIGREGORIO, F., ET AL.: Angiotensin II stimulates endothelin-1 release from human endothelial cells. Recent Progr. Med. 84: 248-253, 1993.
65. CLANCY, R. M., LESZCZYNSKA-PIZIAK, J., AND ABRAMSON, S. B.: Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on NADPH oxidase. J. Clin. Invest. 90: 1116-1121, 1992.
66. CLOWES, A. W., AND KARNOVSKY, M. J.: Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature (Lond.) 265: 625-627, 1977.
67. COHEN, J. I., AND SEIDEL, K. E.: Absence of varicella-zoster virus glycoprotein V does not alter growth of VZV in vitro or sensitivity to heparin. Gen. Virol. 75: 3087-3093, 1994.
68. COHN, J. S.: Postprandial lipid metabolism. Curr. Opin. Lipidol. 5: 185-190, 1994.
69. COLLINS, T.: Endothelial nuclear factor-kB and the initiation of the atherosclerotic lesion. Lab. Invest. 68: 499-508, 1993.
70. COLOTTA, F., SCIACCA, F. L., SIRONI, M., LUINI, W., RABIET, M. J., AND MANTOVANI, A.: Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am. J. Pathol. 144: 975-985, 1994.
71. CONSTANTINIDES, P., AND HARKEY, M.: Electron microscopic exploration of human endothelium in step-serial sections of early and advanced atherosclerotic lesions. Ann. N.Y. Acad. Sci. 598: 113-124, 1990.
72. COOKE, J. P., AND TSAO, P.: Cellular mechanisms of atherogenesis and the effects of nitric oxide. Curr. Opin. Cardiol. 7: 799-804, 1992.
73. CRAWFORD, D. W., AND BLANKENHORN, D. H.: Arterial wall oxygenation, oxyradicals and atherosclerosis. Atherosclerosis. 89: 97-108, 1991.
74. CRUTCHLEY, D. J., AND QUE, B. G.: Copper induced tissue factor expression in human monocyte TMP-1 cells and its inhibition by antioxidants. Circulation. 92: 238-243, 1995.
75. CUPP, M., BENSADOUN, A., AND MELFORD, K.: Heparin decreases the degradation rate of lipoprotein lipase in adipocytes. J. Biol. Chem. 262: 6283-6288, 1987.
76. 1 inhibitor plus heparin in prevention of complement-mediated activation of endothelial cells in a model of xenograft hyperacute rejection. Transplant. Proc. 26: 1246-1247, 1994.
77. DAUGHERTY, A., RATERI, D. L., DUNN, J. L., AND HEINECKE, J. W.: Human atherosclerotic lesions contain myeloperoxidase, a phagocytic enzyme that catalyzes oxidation reactions (abstract). Circulation. 88(suppl. 4): 0155, 1994.
78. DEMACKER, P. N. M., REIJNEN, I. G. M., KATAN, M. B., STUYT, P. M. J., AND STALENHOEF, A. F. H.: Increased removal of remnants of triglyceride-rich lipoproteins on a diet rich in polyunsaturated fatty acids. Eur. J. Clin. Invest. 21: 197-203, 1991.
79. 2 by heparin. Biochim. Biophys. Acta. 1046: 242-248, 1990.
80. 1-INH and heparan sulfate can prevent discordant rejection. Transplant. Proc. 26: 1172-1173, 1994.
81. DOHERTY, T. M., AND DETRANO, R. C.: Coronary arterial calcification as an active process: a new perspective on an old problem. Calcif. Tissue Int. 54: 224-230, 1994.
82. DOUGLAS, S. A., LOUDUN, C., AND VICKERY-CLARK, L. M.: A role for endogenous ET-1 in neointimal formation after rat carotid artery balloon angioplasty. Circ. Res. 75: 190-197, 1994.
83. DRAEJER, R., ATSMA, D. E., VAN DER LAARSE, A., AND VAN HINSBERGH, V. W. M.: c-GMP and nitric oxide modulate thrombin-induced increased endothelial permeability: regulation via different pathways in human aortic and umbilical vein endothelial cells. Circ. Res. 76: 199-208, 1995.
84. DRAKELY, S. J., AND FURNESS, P. N.: Heparin inhibits the binding of immune complexes to cultured rat mesangial cells. Nephrol. Dial. Transplant. 9: 1084-1089, 1994.
85. 2+ stores and protein synthesis in human endothelial cells. Circ. Res. 76: 388-395, 1995.
86. 2 by heparin. Eur. J. Biochem. 221: 481-490, 1994.
87. DUBEY, R. K., JACKSON, E. K., AND LUSCHER, T. F.: Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cells: role of cyclic nucleotides and AN receptors. J. Clin. Invest. 96: 141-149, 1995.
88. DUDMAN, N. P. B., HICKS, C., WANG, J., AND WILCKEN, C. K.: Human arterial endothelial cell detachment in vitro and its promotion by homocysteine and cysteine. Atherosclerosis. 91: 77-83, 1991.
89. DURRINGTON, P. N.: How HDL protects against atheroma. Lancet. 342: 1315-1316, 1993.
90. DZAU, V. J.: Significance of the vascular renin-angiotensin pathway. Hypertension. 8: 553-559, 1986.
91. EDELMAN, E. R., PUKAC, L. A., AND KARNOVSKY, M. J.: Protamine and protamine insulin exacerbate the vascular response to injury. J. Clin. Invest. 91: 2308-2313, 1993.
92. EDENS, R. E., LINHARDT, R. J., BELL, C. S., AND WEILER, J. M.: Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum. Immunopharmacology. 27: 145-153, 1994.
93. EDWARDS, I. J., AND WAGNER, W. D.: Cell surface heparan sulfate proteoglycans and chondroitin sulfate proteoglycans of arterial smooth cells. Am. J. Pathol. 140: 193-205, 1892.
94. EDWARDS, I. J., AND WAGNER, W. D.: Removal of newly-synthesized proteoglycans linked to enhanced proliferation of aortic smooth muscle cells (abstract). FASEB J. 9: 2392, 1995.
95. EDWARDS, I. J., XU, H., WRIGHT, M. J., AND WAGNER, W. D.: IL-1 upregulates decorin production by arterial smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 14: 1302-1309, 1994.
96. EGASHIRA, K., INOU, T., HIROOKA, V., YAMADA, A., MARUDA, Y., KAI, H., SUGAMACHI, M., SUZUKI, S., AND TAGESHITA, A.: Impaired coronary risk factors and proximal atherosclerotic lesions. J. Clin. Invest. 91: 29-37, 1993.
97. EKRE, H. R., NAPARSTEK, Y., LIDER, O., HYDAN, P., HAGERMARK, D., NILSSON, T., VLODOVSKY, I., AND COHEN, I.: Anti-inflammatory effects of heparin and its derivatives: inhibition of complement and of lymphocyte migration. Adv. Exp. Biol. Med. 313: 329-340, 1992.
98. EMBER, J. E., SANDERSON, S. D., HUGLI, T. E., AND MORGAN, E. L.: Induction of IL-8 synthesis from monocytes by human C5a anaphylotoxin. Am. J. Pathol. 144: 393-403, 1994.
99. ENGELBERG, H.: Human endogenous plasma lipemia clearing activity: observations in 482 individuals. J. Appl. Physiol. 13: 375-382, 1958.
100. ENGELBERG, H.: Plasma heparin levels in normal man. Circulation. 23: 578-581, 1961a.
101. ENGELBERG, H.: Plasma heparin levels: correlation with serum cholesterol and low-density lipoproteins. Circulation. 23: 573-577, 1961b.
102. ENGELBERG, H.: Mechanisms involved in the reduction of serum triglycerides in man upon adding unsaturated fats to the normal diet. Metabolism. 15: 796-803, 1966.
103. ENGELBERG, H.: Serum lipemia: an overlooked cause of tissue hypoxia. Cardiology. 70: 273-279, 1983.
104. ENGELBERG, H.: Heparin and the atherosclerotic process. Pharmacol. Rev. 36: 91-110, 1984.
105. ENGELBERG, H.: Update on the relationship of heparin to atherosclerosis and its thrombotic complications. Semin. Thromb. Hemost. 14(suppl.): 88-105, 1988.
106. ENGELBERG, H.: Heparin and the prevention of atherosclerosis. In Basic Research and Clinical Application, 217 pp., Wiley-Liss, New York, 1990.
107. ENGELBERG, H.: Low-dose intermittent heparin therapy decreases plasma fibrinogen levels. Semin. Thromb. Haemost asis. 17: 211-215, 1991.
108. ESKO, J. D.: Genetic analysis of proteoglycan structure, function and metabolism. Curr. Opinion Cell Biol. 3: 805-816, 1991.
109. ESKO, J. D., STEWART, T. E., AND TAYLOR, W. H.: Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc. Natl. Acad. Sci. USA 82: 3197-3201, 1985.
110. FAGER, G., CAMEJO, G., AND BONDGERS, G.: The PDGF A-chain contains an amino acid sequence that specifically binds to heparin causing inactivation of the growth factor. Scand. J. Clin. Lab. Invest. 199: 33-36, 1990.
111. FAGER, G., CAMEJO, G., AND BONDGERS, G.: Heparin-like glycosaminoglycans and phenotype of human arterial smooth muscle cells in vitro I. Evidence for reversible binding and interaction of PDGF by heparin. In Vitro Cell Dev. Biol. 28: 168-175, 1992.
112. FAGER, G., CAMEJO, G., OLSSON, V., OSTERGREN-LUNDEN, G., LUSTIG, F., AND BONDGERS, G.: Binding of PDGF and LDL to glycosaminoglycan species produced by human arterial smooth muscle cells. J. Cell Physiol. 163: 380-392, 1995.
113. FALK, R. J., TERRELL, I. S., CHARLES, L. A., AND JENNETTE, J. C.: Anti-neutrophil cytoplasmic antibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc. Natl. Acad. Sci. USA 87: 4115-4119, 1990.
114. FARHY, R. D., CARRETERO, O. A., Ho, K-L., AND SCICLI, A. G.: Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ. Res. 72: 1202-1210, 1993.
115. FARQUI, R. M., AND DICORLETO, P. E.: Mechanisms of monocyte recruitment and accumulation. Br. Heart J. 69(suppl.): 519-529, 1993.
116. 2-ATPase inhibition in intact HL-60 granulocytes. Biochem. J. 302: 155-162, 1994.
117. FEENER, E. P., NORTHRUP, J. N., AIELLO, L. P., AND KING, G. L.: Angiotensin II induces plasminogen activator inhibitor 1 and 2 expression in vascular endothelial and smooth muscle cells. J. Clin. Invest. 95: 1353-1362, 1995.
118. FOREMAN, K. E., VAPORCIYAN, A. A., BONISH, B. K., JONES, M. L., JOHNSON, K. J., GLOVSKY, M., ET AL.: C5a-induced expression of P-selectin in endothelial cells. J. Clin. Invest. 94: 1147-1155, 1994.
119. 2 purified from an inflammatory exudate. Biochem. 25: 8381-8385, 1986.
120. FOSSE, E., MOEN, O., JOHNSON, E., SEMB, G., BROCKMEIER, V., MOLLNES, T. E., ETAL.: Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann. Thorac. Surg. 58: 473-477, 1994.
121. FOXALL, C., WATSON, S. R., DOBENKO, D., FENNIE, C., LASKY, L. A., KISO, M., HASEGAWA, A., ASA, D., AND BRANDLEY, D. K.: The three members of the selectin family recognize a common carbohydrate epitope, the Sialyl-Lewis oligosaccharide. J. Cell Biol. 117: 895-902, 1992.
122. FREYSCHUSS, A., STIKO-RAHM, A., SWEDENBORG, J., HENRICKSON, P., BJORKLEN, I., BERGLUND, L., AND NILSSON, J.: Antioxidant treatment inhibits the development of intimai thickening after balloon injury of the aorta in hypercholesterolemic rabbits. J. Clin. Invest. 91: 1282-1288, 1993.
123. FRIEDL, H. P., TILL, G. O., RYAN, U. S., AND WARD, P. A.: Mediator induced activation of xanthine oxidase in endothelial cells. FASEB J. 3: 2512-2518, 1989.
124. FRYER, R. H., WILSON, B. D., GUBLER, B. D., FITZGERALD, L. A., AND RODGERS, G. M.: Homocysteine, a risk factor for premature vascular disease and thrombosis induces tissue factor activity in endothelial cells. Arterioscler. Thromb. 13: 1327-1333, 1993.
125. FUJIGAKI, Y., BATSFORD, F. R., BITTERSUERMANN, D., AND VOGT, A.: Complement system promotes transfer of immune complexes across glomerular filtration barrier. Lab. Invest. 72: 25-33, 1995.
126. FUKAMI, K., AND TAKENAWA, T.: Phosphatidic acid that accumulates in PDGF-stimulated Balb 3T3 cells is a potential mitogenic signal. J. Biol. Chem. 267: 10988-10993, 1992.
127. FURIE, B., AND FURIE, B.C.: The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand. Thromb. Haemostasis. 74: 224-227, 1995.
128. FURNESS, P. N., AND DRAKELEY, S.: Heparin causes partial removal of glomerular antigen deposits by a mechanism independent of its anticoagulant properties. J. Pathol. 168: 217-220, 1992.
129. FUSTER, V.: Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 90: 2126-2145, 1994.
130. GAGNE, E., GEWEST, J., ZHANG, H., CLARKE, L. A., AND HAYDEN, M. R.: Analysis of DNA changes in the LPL gene in patients with familial combined hyperlipidemia. Arterioscler. Thromb. 14: 1250-1257, 1994.
131. GALIS, Z. S., SUKHOVA, G. A., LARK, M. W., AND LIBBY, P.: Increased expression of matrix metalloproteases and matrix-degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94: 2493-2503, 1994.
132. GALLAGHER, J. T., LYON, M., AND STEWART, W. P.: Structure and function of heparan sulfate proteoglycans. Biochem. J. 236: 313-325, 1986.
133. GALLO, G. R., COUDIA-GLASER, T., EMANCIPATOR, S. M., AND LAMM, M. A.: Nephrogenicity and differential distribution of glomerular immune complexes related to immunogen charge. Lab. Invest. 48: 353-362, 1983.
134. GALTON, D. J., MATTA, R. K., AND CAVANNA, J.: Polymorphisms of the lipoprotein lipase gene and premature atherosclerosis. J. Intern. Med. 236(suppl. 736): 69-74, 1994.
135. GARCIA, J. G. N., AND SCHAPHORST, K. L.: Regulation of endothelial cell gap formation and paracellular permeability. J. Invest. Med. 43: 117-126, 1995.
136. GE, M., RYAN, T. J., LUM, H., AND MALIK, A. B.: Fibrinogen degradation product Fragment D increases endothelial monolayer permeability. Am. J. Physiol. 261: L283-L289, 1991.
137. GEARING, A. J. H., BECKETT, P., CHRISTODOULOU, M., CHURCHILL, M., CLEMENTS, J., DAVIDSON, A. H., ET AL.: Processing of tumor necrosis factor - a precursor by matrix metalloproteases. Nature (Lond.) 370: 555-557, 1994.
138. GELLER, R. L., IHRCKE, N. S., MAINES, J., LINDMAN, B. J., AND PLATT, J. L.: Loss of heparan sulfate proteoglycans as a manifestation of cellular immunity in vivo and in vitro. Transplant. Proc. 25: 144-145, 1993.
139. GELLER, R. L., IHRCKE, N. S., AND PLATT, J. L.: Release of endothelial cell-associated heparan sulfate proteoglycans by activated T cells. Transplantation. 57: 770-774, 1994.
140. GERDES, C., GERDES, L. V., HANSEN, P. S., AND FAERGMAN, O.: Polymorphisms in the lipoprotein gene and their association with plasma lipid concentrations in 40-year-old Danish men. Circulation. 92: 1765-1769, 1995.
141. GERRITY, R. G., RICHARDSON, M., SOMER, J. B., BELL, F. P., AND SCHWARTZ, C. J.: Endothelial cell morphology in areas of in vivo Evans blue uptake in the aorta of young pigs. Am. J. Pathol. 89: 313-326, 1977.
142. GHOSH, T. K., EIS, P. S., MULLANEY, J. M., EBERT, C. L., AND GILL, D. L.: Competitive, reversible, and potent antagonism of inositol 1,4,5 triphosphate-activated calcium release by heparin. J. Biol. Chem. 263: 11075-11079, 1988.
143. GOCKERMAN, A., AND CLEMMONS, D. R.: Porcine aortic smooth muscle cells secrete a serum protease for insulin-like growth factor binding protein-2. Circ. Res. 76: 514-521, 1995.
144. GOLDBERG, I. J., LE, N-A., AND GINSBERG, H. N.: Lipoprotein metabolism during acute inhibition of lipoprotein lipase in the cynomolgus monkey. J. Clin. Invest. 81: 561-568, 1988.
145. GOLDBERG, M. A., AND SCHNEIDER, T. J.: Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J. Biol. Chem. 269: 4355-4359, 1994.
146. GOROG, P., AND BORN, G. V. R.: Increased uptake of low density lipoproteins and fibrinogen by arterial walls after removal of sialic acids from the endothelial surface. Br. J. Exp. Pathol. 63: 447-455, 1982a.
147. GOROG, P., AND BORN, G. V. R.: Increased adhesiveness of granulocytes in rabbit ear chamber blood vessels perfused with neuraminidase. Microvasc. Res. 23: 380-384, 1982b.
148. GOROG, P., AND PEARSON, J. D.: Surface determinants of low density lipoprotein uptake by endothelial cells. Atherosclerosis. 53: 21-29, 1984.
149. GOROG, P., PIPER, J., RIDLER, C. D., AND KOVACS, I. B.: Heparin, unfractionated and low molecular weight, inhibit physiologically relevant platelet reactivity in a native blood in vitro (abstract). Thromb. Haemostasia. 65: 849, 1991.
150. GORSKI, A., AND LAGODZINSKI, Z.: Oral heparin prolongs survival of skin allografts. Arch. Immunol. Ther. Exp. 39: 557-62, 1991.
151. GRAINGER, D. G., MITCHELL, C. M., WATSON, V., METCALFE, J. C., AND WEISSBERG, P. L.: Heparin decreases the rate of proliferation of rat vascular smooth muscle cells by releasing transforming growth factor-B-like activity from serum. Cardiovasc. Res. 27: 2238-2247, 1993.
152. GRANT, D., LONG, W. F., AND WILLIAMSON, F. B.: Pericellular heparans may contribute to the protection of cells from free radicals. Med. Hypotheses. 23: 67-71, 1987.
153. GRANT, D., LONG, W. F., AND WILLIAMSON, F. B.: A potentiometric study of the interaction of heparin with metal cations. Biochem. J. 285: 477-480, 1992.
154. GREENWALD, L., AND BECKER, R. C.: Expanding the paradigm of the reninangiotensin system and angiotensin converting enzyme inhibitors. Am. Heart J. 128: 997-1009, 1994.
155. GRINDLING, K. K., MINIERI, C. A., OLLERENSHAW, J. D., AND ALEXANDER, R. W.: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74: 1141-1148, 1994.
156. GU, J.-L., VEERAPANA, D., ROSSI, J., NATARAJAN, R., THOMAS, L., AND NADLER, J.: Ribozyme-mediated inhibition of expression of leukocyte 12-lipoxygenase in porcine aortic vascular smooth muscle cells. Circ. Res. 77: 14-20, 1995.
157. GURETZKI, H-J., GERBITZ, K-D., OLGEMOLLER, B., AND SCHLEICHER, E.: Atherogenic levels of low-density lipoprotein alter the permeability and composition of the endothelial barrier. Atherosclerosis. 107: 15-24, 1994.
158. HAJJAR, D. P.: Viral pathogenesis of atherosclerosis: impact of molecular mimicry and viral genes. Am. J. Pathol. 139: 1195-1211, 1991.
159. HALLIWELL, B.: Free radicals, reactive oxygen species and human disease: a critical evaluation with special reference to atherosclerosis. Br. J. Exp. Pathol. 70: 737-757, 1989.
160. HALLIWELL, B.: Reactive oxygen species in living systems: source, biochemistry, and role in human disease. Am. J. Med. 91(suppl. 3C): 145-225, 1991.
161. HAMSTEN, A., KARPE, F., BAVENHOLM, P., AND SILVEIRA, A.: Interactions amongst insulin, lipoproteins and haemostatic function relevant to coronary heart disease. J. Int. Med. 236(suppl. 736): 75-88, 1994.
162. x and sulfated glycans modulate this binding. Biochem. Biophys. Res. Commun. 181: 123-130, 1991.
163. HANSSON, G. K., BONDJERS, G., AND NILSSON, L.-A.: Plasma protein accumulation in injured endothelial cells. Exp. Mol. Pathol. 30: 13-26, 1979.
164. HANSSON, G. K.: Immune and inflammatory mechanisms in the development of atherosclerosis. Br. Heart J. 69(suppl.): 38-41, 1993.
165. HARDINGHAM, T. E., AND FOSANG, A. J.: Proteoglycans: many forms and many functions. FASEB J. 6: 861-870, 1992.
166. HASKER, L. A., HANSON, S. R., AND RUNGE, M. S.: Thrombin hypothesis of thrombin generation and vascular lesion formation. Am. J. Cardiol. 75: 12B-17B, 1995.
167. HASUDA, D. J., STRICKER, J., SIMON, P. L., AND YOUNG, P. R.: Processing of precursor interleukin-1B and inflammatory disease. J. Biol. Chem. 265: 6318-6322, 1990.
168. HATA, A., RIDINGER, D. N., SUTHERLAND, S., EMI, M., SHUHUA, Z., MYERS, R. L., ET AL.: Binding of human lipoprotein lipase to heparin: identification of five critical residues in two distinct segments of the amino terminal domain. J. Biol. Chem. 268: 8447-8457, 1993.
169. 3 integrins: an adhesion modulated by glycosaminoglycans. J. Cell Biol. 119: 945-959, 1992.
170. HAYDEN, M. R., LIU, M. S., AND MA, Y.: Gene environmental interaction and plasma triglyceride levels: the crucial role of lipoprotein lipase. Clin. Genet. 46: 15-18, 1994.
171. HELLER, R. A., AND KRONKE, M.: Tumor necrosis factor receptor-mediated signaling pathways. J. Cell Biol. 126: 5-9, 1994.
172. HERBERT, V., SHAW, S., JAYATILLEKE, E., AND STOPLER-KASDAN, T.: Most free radical injury is iron-related: it is promoted by iron, hemin, holoferritin and vitamin C, and is inhibited by desferoxamine and apoferritin. Stem Cells 12: 289-303, 1994.
173. HERMAN, I. M.: Endothelial cell matrices modulate smooth muscle cell growth, contractile phenotype, and sensitivity to heparin. Hemostasis 20(suppl.): 166-177, 1990.
174. HIEBERT, L. M., AND LIU, J-M.: Heparin protects cultured arterial endothelial cells from damage by toxic oxygen metabolites. Atherosclerosis. 83: 47-51, 1990.
175. HIEBERT, L. M., AND LIU, J-M.: Dextran sulfates protect porcine arterial endothelial cells from free radical injury. Hum. and Exp. Toxicol. 12: 1-7, 1993.
176. HIEBERT, L. M., AND LIU, J-M.: Dextran sulfates protect porcine arterial endothelial cells from free radical injury. Hum. and Exp. Toxicol. 13: 233-239, 1994.
177. HIRAMATSU, K., AND ARIMORI, S.: Increased superoxide production by mononuclear cells of patients with hypertriglyceridemia and diabetes. Diabetes. 37: 832-837, 1988.
178. HLADOVEC, J., AND KORNALIK, F.: Serotonin modifies the endothelial turnover-inhibiting activity of heparan sulfate. Thromb. Res. 73: 265-268, 1994.
179. HOCKING, D., FERRO, T. J., AND JOHNSON, A.: Dextran sulfate inhibits PMN-dependent hydrostatic pulmonary edema induced by tumor necrosis factor. J. Appl. Physiol. 70: 1121-1128, 1991.
180. HOCKING, D., FURO, T. J., AND JOHNSON, A.: Dextran sulfate and heparin sulfate inhibit platelet activating factor-induced pulmonary edema. J. Appl. Physiol. 72: 179-185, 1992.
181. HOFF, H. F., AND WAGNER, W. D.: Plasma LDL accumulation in aortas of hypercholesterolemic swine correlates with modifications in aortic glycosaminoglycan composition. Atherosclerosis. 61: 231-236, 1986.
182. HOLLIMAN, J., SCHMIDT, A., VON BASSEWITZ, D. B., AND BUDDUKE, E.: Relationship of sulfated glycosaminoglycans and cholesterol content in normal and atherosclerotic human aorta. Arteriosclerosis. 9: 154-158, 1989.
183. HOLT, B. D., SHAO, Y., KINOSHITA, A., GABEL, M., HUSAIN, A., AND WALSH, R. A.: Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon. J. Clin. Invest. 95: 1747-1755, 1995.
184. HOLT, C. B., FRANCIS, S. E., GODSDON, P. A., VIOLARIS, A., IZZAT, M. B., AND ANGELINI, G. D.: Release of PDGF in serum-free organ culture of human coronary arteries. Cardiovasc. Res. 28: 1170-1175, 1994.
185. HOLT, G. D., PANGBURN, M. K., AND GINSBURG, V.: Properdin binds to sulfatide and has a sequence homology with other proteins that bind sulfated glycoconjugates. J. Biol. Chem. 265: 2852-2855, 1990.
186. HORIUCHI, S., AND ARAKI, N.: Advanced glycosylation end products of the Maillard reaction and their relation to aging. Gerontology. 40(suppl. 2): 10-15, 1994.
187. HOSOYA, M., BALZARINI, J., SHIGETA, S., AND DECLERQ, E.: Differential inhibitory effects of sulfated polysaccharide polymers on the replication of various megaviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoprotein. Antimicrob. Agents Chemother. 35: 2515-2520, 1991.
188. HUWILER, A., STABEL, S., FABBRO, D., AND PFEILSCHRIFTER, J.: Platelet derived growth factor and angiotensin II stimulate the MAPK cascade in renal mesangial cells: comparison of hypertrophic and hyperplastic agonists. Biochem. J. 305: 777-784, 1995.
189. IDA, H., KURATA, A., AND EGUCHI, K.: Mechanism of inhibitory effect of dextran sulfate and heparin on human T-cell lymphotropic virus type 1-induced syncytium formation in vitro: role of cell-cell contact. Antiviral Res. 23: 143-159, 1994.
190. IMAI, T., HIRATA, Y., EMORI, T., AND MARUMO, F.: Heparin has an inhibitory effect on endothelin-1 synthesis and release by endothelial cells. Hypertension. 21: 353-358, 1993.
191. INSERRA, F., ROMANO, L., DE CAVANAGH, E. M. V., AND FERDER, L.: Cardiovascular changes by long-term inhibition of the renin-angiotensin system in aging. Hypertension. 25: 437-442, 1995.
192. Iozzo, R. V., COHEN, I. R., GRASSEL, S., AND MURDOCH, A. D.: The biology of perlecan: the multifaceted heparan sulfate proteoglycan of basement membranes and pericellular matrices. Biochem. J. 302: 625-639, 1994.
193. JACKSON, R. L., BUSCH, S. J., AND CARDIN, A. D.: Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol. Rev. 71: 481-539, 1991.
194. JACOB, H. S.: Vascular shear forces and atherogenesis; roles of shear-provoked endothelial viral infection and heme iron accumulation. Perspect. Biol. Med. 38: 114-124, 1994.
195. JEANNIN, P., DEBNISTE, Y., GOSSET, P., MOIET, S., LASSALLE, P., HAMID, O., TSICOULOS, A., AND TONNEL, A. B.: Histamine induces interleukin-8 secretion by endothelial cells. Blood. 84: 2229-2233, 1994.
196. JESKE, W., LORMEAU, J. C., CALLAS, D., IQBAL, O., HOPPENSTAEDT, D., AND FAREED, J.: Antithrombin-III affinity dependence on the anticoagulant, antiprotease, and tissue factor pathway inhibitor actions of heparin. Thromb. Haemostasis. 21: 193-200, 1995.
197. JI, Z-S., FAZIO, A., AND MAHLEY, R. W.: Variable heparan sulfate proteoglycans binding of apo-lipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J. Biol. Chem. 269: 13421-13428, 1994.
198. JI, Z-S., SANAN, D. A., AND MAHLEY, R. W.: Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. J. Lipid Res. 36: 583-592, 1995.
199. JIANG, K., KHURSIGARA, G., AND RUBIN, R. L.: Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science (Wash. DC) 266: 810-813, 1994.
200. JOHNSON, K. J., WARD, P. A., KUNKEL, R. G., AND WILSON, B. S.: Mediation of IgA-induced lung injury in the rat. Lab. Invest. 54: 499-506, 1986.
201. JOHNSON, R. J., GUGGENHEIM, S. J., KLEBANOFF, S. J., OCHI, R. F., WASS, A., BAKER, P., SCHULZE, M., AND COUSER, W. G.: Morphologic correlates of glomerular oxidant injury induced by myleoperoxidase-hydrogen peroxide-halide system of the neutrophil. Lab. Invest. 58: 294-301, 1988.
202. JOHNSON-TIDEY, R. R., MCGREGOR, J. L., TAYLOR, P. R., AND POSTON, R. N.: Increase in the adhesion molecule P-selectin in endothelium overlying atherosclerotic plaques. Am. J. Pathol. 144: 952-961, 1994.
203. JOUAVILLE, L. S., ICHAS, F., HOLMUHAMEDOV, E. L., CAMACHO, P., AND LECHLEITER, J. D.: Synchronization of calcium waves by mitochondrial substrates in Xenopus laevis oocytes. Nature (Lond.) 377: 438-441, 1995.
204. JOURDAN, A., AGUEJOUF, O., IMBAULT, P., DOUTREMEPUICH, F., INAMO, J., AND DOUTREMEPUICH, C.: Experimental thrombosis model induced by free radicals: application to aspirin and other different substances. Thromb. Res. 79: 109-123, 1995.
205. KAJI, T., AKAI, T., HAYASHI, T., AND SAKURAGAWA, N.: Thrombin decreases glycosaminoglycan content of endothelial cells in culture. Thromb. Res. 61: 375-381, 1991.
206. KANER, R. J., IOZZO, R. V., ZIALE, Z., AND KEFALIDES, N. A.: Inhibition of proteoglycan synthesis in human endothelial cells with human HSV-1 in vitro. Am. J. Resp. Cell. Mol. Biol. 2: 423-431, 1990.
207. KARLINSKY, J. B., ROUNDS, S., AND FARBER, H. W.: Effects of hypoxia on heparan sulfate in bovine aortic and pulmonary artery endothelial cells. Circ. Res. 71: 782-789, 1992.
208. KARPE, F., STEINER, G., OLIVECRONA, T., CARLSON, L. A., AND HAMSTEN, A.: Metabolism of triglyceride-rich lipoproteins during alimentary lipemia. J. Clin. Invest. 91: 748-758, 1993.
209. KARPE, R., OLIVECRONA, T., WALDIUS, G., AND HAMSTEN, A.: Lipoprotein lipase in plasma after an oral fat load: relation to free fatty acids. J Lipid Res. 33: 975-984, 1992.
210. KATSUDA, S., BOYD, H. C., FLIGNER, C., ROSS, R., AND GOWN, A. M.: Human atherosclerosis III. Immunocytochemical analysis of the cell composition of lesions of young adults. Am. J. Pathol. 140: 907-914, 1992.
211. KAWAGUCHI, H., SAWA, H., AND YASUDA, H.: Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. J. Mol. Cell Cardiol. 22: 839-842, 1990.
212. KELLER, K. L., BRAUER, P. R., AND KELLER, J. M.: Isolation of Swiss 3T3 cell variants with altered heparan sulfate. Exp. Cell Res. 179: 137-158, 1988.
213. KELLER, K. L., KELLER, J. M., AND MOY, J. N.: Heparan sulfates form Swiss mouse 3T3 and SV3T3 cells: O-sulfate differences. Biochemistry. 19: 2529-2536, 1990.
214. KENAGY, R. D., AND CLOWES, A. W.: A possible role for MMP-2 and MMP-1 in the migration of primate arterial smooth muscle cells through native matrix. Ann. N.Y. Acad. Sci. 732: 462-464, 1994.
215. KENAGY, R. D., AND CLOWES, A. W.: Regulation of baboon arterial smooth muscle cell plasminogen activators by heparin and growth factors. Thromb. Res. 77: 55-61, 1995.
216. KENAGY, R. D., NIKKARI, S. T., WELGUS, H. G., AND CLOWES, A. W.: Heparin inhibits the induction of 3 matrix metalloproteases (stromelysin, 92Kd gelatinase, and collagenase) in primate arterial smooth muscle cells. J. Clin. Invest. 93: 1987-1993, 1994.
217. KEY, N. S., PLATT, J. L., AND VERCELLOTTI, G. M.: Various endothelial cell proteoglycans are susceptible to cleavage by neutrophils. Arterioscler. Thromb. 12: 836-842, 1992.
218. KIENER, P. A., RANKIN, B. M., DAVIS, P. M., YOCUM, S. A., WARR, G. A., AND GROVE, R. I.: Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler. Thromb. Vasc. Biol. 15: 990-999, 1995.
219. KIRSCHENHOFER, H. L., METCALFE, J. C., WEISSBERG, P. L., AND GRAINGER, D. J.: Proliferation of human aortic vascular smooth muscle cells in culture is modulated by active TGF-B. Cardiovasc. Res. 29: 848-855, 1995.
220. KJELLEN, L., AND LINDAHL, V.: Proteoglycans: structure, function and metabolism. Curr. Opinion Cell Biol. 3: 805-816, 1991.
221. 2-chloride system. Am. J. Pathol. 143: 907-917, 1993.
222. KLEIN, N. J., SHENNAN, G. I., HEYDERMAN, R. S., AND LEVIN, M.: Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. J. Cell Sci. 102: 821-832, 1992.
223. KNAUSS, T. C., JAFFER, F. E., AND ABBOUD, H. E.: Phosphatidic acid modulates DNA synthesis, phospholipase C, and PDGF mRNA in cultured mesangial cells: role of protein kinase C. J. Biol. Chem. 265: 14457-14463, 1990.
224. KOBAYASHI, M., SHIMADA, K., AND OZAWA, T.: Human interleukin-1 and tumor necrosis factor-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells. J. Cell. Physiol. 144: 383-390, 1990.
225. KOHNO, M., YOKOKAWA, K., HORIO, T., IKEDA, M., KURIHARA, N., MANDAL, ET AL.: Heparin inhibits endothelin-1 production in cultured rat mesangial cells. Kidney Int. 45: 137-142, 1994.
226. KOKENYESI, R., AND SILBERT, J. E.: Formation of heparan sulfate or chondroitin/dermatan sulfate on recombinant domain of mouse perlecan expressed in Chinese hamster ovary cells. Biochem. Biophys. Res. Commun. 211: 262-267, 1995.
227. KOLIPARA, L. V. P., PLEASS, H. C. C., TAYLOR, R. M. R., PROUD, G., FORSYTHE, J. L. R., AND KIRBY, J. A.: Heparin antagonizes the induction of class II MHC molecules by interferon gamma. Transplantation. 58: 1426-1429, 1994.
228. KOLPAKOV, V., GORDON, D., AND KULIK, T. J.: Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells. Circ. Res. 76: 305-309, 1995.
229. KOUREMBANAS, E., MCMILLAN, L. P., LEUNG, G. K., AND FULLER, D. V.: Nitric oxide regulates the expression of vasoconstrictors by vascular endothelial cells under both normoxia and hypoxia. J. Clin. Invest. 92: 99-104, 1993.
230. KOWALA, M. C., GROVE, R. I., AND ABERG, G.: Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters independently of blood pressure and plasma lipids. Atherosclerosis. 108: 61-72, 1994.
231. KOWALA, M. C., ROSE, P. M., STEIN, P. D., GOLLER, N., RECCE, R., BEYER, S., ET AL.: Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters. Am. J. Pathol. 146: 819-826, 1995.
232. KUBER, P., SUZUKI, M., AND GRAINGER, D. N.: Platelet active factor-induced microvascular dysfunction: role of adherent leukocytes. Am. J. Physiol. 258: G158-G163, 1990.
233. KUME, S., TAKEYA, M., AND MORI, T.: Immunohistochemical and ultrasound detection of AGE in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. Am. J. Pathol. 147: 654-667, 1995.
234. KUSELS, H., BEGUIN, S., ANDREE, H., AND HEMKER, H. C.: Measurements of thrombin generation in whole blood: the effect of heparin and aspirin. Thromb. Haemostasis. 72: 78-83, 1994.
235. LARNKJAER, A., NYKJAER, A., OLIVECRONA, G., THORGERSEN, H., AND OSTERGAARD, P. B.: Structure of heparin fragments with high affinity for lipoprotein lipase and inhibition of lipoprotein lipase binding to the alpha 2-macroglobulin receptor/LDL receptor related protein by heparin fragments. Biochem. J. 307: 205-214, 1995.
236. LASKY, L. A.: Combinatorial mediators of inflammation. Curr. Biol. 3: 366-368, 1993.
237. LENARDO, M. J., AND BALTIMORE, D.: NF-kB: a pleiotropic mediator of inducible and tissue-specific gene control. Cell. 58: 227-229, 1989.
238. LENTZ, S. R., AND SADLER, J. E.: Inhibition of thrombomodulin surface expression and protein c activation by the thrombogenic agent homocysteine. J. Clin. Invest. 88: 2026-2031, 1991.
239. LESNICK, P., DENTON, C., VONICA, A., MOREAU, M., AND CHAPMAN, M. J.: Tissue factor pathway inhibitor activity associated with low density lipoproteins is inactivated by cell and copper-mediated oxidation. Arterioscler. Thromb. Vasc. Biol. 15: 1121-1130, 1995.
240. LEVIN, E. R.: Endothelins. New Eng. J. Med. 333: 356-362, 1995.
241. LEY, K., LINNEMAN, G., MEINEN, M., STODMAN, L. M., AND GOEGHTGENS, P.: Fucoidin, but not yeast phosphomannan, inhibits leukocyte rolling in rat mesentery. Blood. 81: 177-185, 1993.
242. LI, X. A., HATANAKA, H., ISHIBASHI-UEDA, H., YUTANI, C., AND YAMAMOTO, A.: Characterization of serum amyloid P component from human aortic atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 15: 252-257, 1995a.
243. LI, Y. M., TAN, A. X., AND VLASSARA, H.: Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nature Med. 1: 1057-1061, 1995b.
244. LIDHOLT, K., ERIKSSON, I., AND KJELLEN, L.: Heparan proteoglycans synthesized by mouse mastocytoma contain chondroitin sulfates. Biochem. J. 311: 233-238, 1995.
245. LIGHT, JR., J. T. BELLAN, J-A., ROBERTS, M. P., FORCE, S. D., CHEN, LI, KERSTEIN, M. D., KADOWITZ, P. J., AND MCNAMARA, D. B.: Heparin treatment enhances the recovery of neoendothelial acetylcholine-induced vascular relaxation after balloon catheter injury in the rabbit aorta. Circulation. 88(suppl. 11): 413-419, 1993.
246. LINDBOM, L., XIE, X., RAUD, J., AND HEDQUIST, P.: Chemoattractant-induced firm adhesion of leukocytes to vascular endothelium in vivo is critically dependent on initial leukocyte rolling. Acta Physiol. Scand. 146: 415-421, 1992.
247. LIU, Z., AND PERLIN, A. S.: Evidence of a selective free radical degradation of heparin mediated by the cupric ion. Carbohydr. Res. 255: 183-191, 1994.
248. LONN, E. M., YASUF, S., AND JHA, P.: Emerging role of angiotensin converting enzyme inhibitors in cardiac and vascular protection. Circulation. 90: 2056-2068, 1994.
249. LORTAT-JACOBS, H., AND GRIMAUD, J.-A.: Interferon gamma c terminal function: new working hypothesis. Heparan sulfate and heparin, new targets for IFN-Gamma, protect, relax the cytokine and regulate its activity. Cell Mol. Biol. 37: 253-260, 1991.
250. LOSCALZO, J.: The relationship between atherosclerosis and thrombosis. Circulation. 86(suppl. 111): 95-99, 1992.
251. LUCCHESI, P. A., AND BERK, B. C.: Regulation of sodium-hydrogen exchange in vascular smooth muscle cells. Cardiovasc. Res. 29: 172-7, 1995.
252. LUSCHER, T. F., BOULANGER, C. M., DOHI, Y., AND YANG, Z.: Endothelium-derived contracting factors. Hypertension 19: 117-130, 1992.
253. LUSCINDER, F. W., AND LAWLER, J.: Integrins as dynamic regulators of vascular function. Faseb. J. 8: 929-938, 1994.
254. MACDUNALD, S. M., RAFNAR, T., LANGDON, J., AND LICHTENSTEIN, L. M.: Molecular identification of an IgE-dependent histamine-releasing factor. Science 269: 688-90, 1995.
255. MAEDA, H., AND AKAIKE, T.: Oxygen free radicals as pathogenic molecules in viral diseases. Proc. Soc. Exp. Biol. Med. 198: 721-7, 1991.
256. MAJACK, R. A.: Beta-type transforming growth factor specifies organizational behavior in vascular smooth muscle cell cultures. J. Cell Biol. 105: 465-471, 1987.
257. MAJESKY, M. W., DAEMEN, M., AND SCHWARTZ, S. M.: Alpha 1 adrenergic stimulation of PDGF A-chain gene expression in rat aorta. J.B.C. 265: 1082-1088, 1990.
258. MALINOW, M. R., NIETO, F. J., SZKLO, M., CHAMBLESS, L. E., AND BOND, G.: Carotid artery intimal-medial wall thickening and plasma homocysteine in asymptomatic adults. Circulation. 87: 1107-1113, 1993.
259. MANGIARNA, E. T., PALMER, V. L., LLOYD, L. L., AND MCCUMBER, W. D.: PDGF mediates angiotensin II-induced proliferation of smooth muscle (abstract). FASEB J. 8: 3500, 1994.
260. MARIU, N., OFFERMAN, M. K., SWERLICK, R., KUNSEH, C., ROSEN, C. A., AHMAD, M., ALEXANDER, R. W., AND MEDFORD, R. M.: Vascular cell adhesion molecule gene 1 transcription and expression are regulated through an antioxidant-sensitive mechanism. J. Clin. Invest. 92: 1866-1874, 1993.
261. MARKS, A. R.: Calcium channels expressed in vascular smooth muscle cells. Circulation. 86(suppl. III): 61-67, 1992.
262. MARMUR, J. D., POON, M., ROSSIKHINA, M., AND TAUBMAN, M. B.: Induction of PDGF-responsive genes in vascular smooth muscle: implication for early response to vessel injury. Circulation. 86(suppl. 111): 53-60, 1992.
263. MARTIN, J. F., BOOTH, R. F. G., AND MONCADA, S.: Arterial wall hypoxia following thrombosis of the vasa vasorum is an initial lesion in atherosclerosis. Eur. J. Clin. Invest. 21: 355-359, 1991.
264. MASON, I. J.: The ins and outs of fibroblast growth factors. Cell. 78: 547-552, 1994.
265. MATIC, M., LEVEUGLE, B., AND FILLIT, H. M.: Tumor necrosis factor-alpha alters the metabolism of endothelial cell proteoglycans. Autoimmunity. 18: 275-284, 1994.
266. MATTANA, J., AND SINGHOL, P. C.: Heparin attenuates the effect of mitogenic vasoconstrictors on mesangial cell proliferation and handling of IgG complexes. J. Pharmacol. Exp. Ther. 273: 80-87, 1995.
267. ++ channel in planar bilayers. Cell Calcium. 12: 505-514, 1991.
268. MCCAFFREY, T. A., AND FALCONE, D. J.: Evidence for an age-related dysfunction in the antiproliferative response to transforming growth factor-B in vascular smooth muscle cells. Mol. Biol. Cell. 4: 315-322, 1993.
269. MCCAFFREY, T. A., FALCONE, D. J., BRAYTON, C. P., AGARWOL, L. A., WELT, F. P., AND WEKSLER, B. B.: Transforming growth factor-B activity is potentiated by heparin via dissociation of the TGF-B/alpha-2 mcg inactive complex. J. Cell Biol. 109: 441-448, 1989.
270. MCCAFFREY, T. A., FALCONE, D. J., AND DU, B.: Transforming growth factor-B is a heparin-binding protein: identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-B. J. Cell. Physiol. 152: 430-440, 1992.
271. MCCAFFREY, T. A., NICHOLSON, A. C., SZABO, P. E., WEKSLER, M. E., AND WEKSLER, B. B.: Aging and arteriosclerosis: the increased proliferation of arterial smooth muscle cells isolated from old rat is associated with increased PDGF-like activity. J. Exp. Med. 167: 163-174, 1988.
272. MCGEEHAN, G. M., BECHERER, J. D., BAST, JR., R. C., BOYER, C. M., CHAMPION, B., CONNOLLY, K. M., ET AL.: Regulation of tumor necrosis factor-a processing by a matrix metalloprotease inhibitor. Nature (Lond.) 370: 558-561, 1994.
273. 3 participation in monocyte adhesion to different surfaces. Proc. Natl. Acad. Sci. USA 91: 10119-10123, 1994.
274. MELNICK, G. F., LADOULIS, C. T., AND CAVALLO, T.: Decreased anionic groups and increased permeability precede deposition of immune complexes in glomerular capillary walls. Am. J. Pathol. 105: 114-120, 1981.
275. MELNICK, J. L., ADAM, E., AND DEBAKEY, M. E.: Cytomegalovirus and atherosclerosis. Eur. Heart J. 14(suppl. K): 30-38, 1993.
276. MIESENBOCK, G., HOLZL, B., FOGER, B., BRANDSTEINER, E., PAULWEBER, B., SANDHOFER, F., AND PATSCH, J. R.: Heterozygous lipoprotein lipase deficiency due to a missence mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities. J. Clin. Invest. 91: 448-455, 1993.
277. MILLER, M. D., AND KRANGEL, M. S.: Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Crit. Rev. Immunol. 12: 17-46, 1992.
278. MILLER, R. A., AND BRETIGAN, B. E.: The formation and biologic significance of phagocyte-derived oxidants. J. Invest. Med. 43: 39-48, 1995.
279. MITCHELL, R. J., EARL, L., BRAY, P., FRIPP, Y. J., AND WILLIAMS, J.: DNA polymorphisms at the lipoprotein lipase gene and their association with quantitative variation in the plasma high density lipoproteins and triglycerides. Hum. Biol. 66: 383-397, 1994.
280. MIYAGAWA, J-I., HIGASHIYAMA, S., KAWATI, S. Y., INUI, S., TAMURA, K., YAMAMOTO, M., NISHIDA, T., NAKAMURA, S., YAMASHITA, Y., MATSUZAWA, N., AND TANIGUCHI, H.: Localization of heparin-binding EGF-like growth factor in smooth muscle cells and macrophages of human atherosclerotic plaques. J. Clin. Invest. 95: 404-411, 1995.
281. MOHLER, K. M., SLEATH, P. R., FITZNER, J. N., CERRETTI, D. P., ALDERSON, M., KERWAR, S. S., ET AL.: Protection against a lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing. Nature (Lond.) 370: 218-220, 1994.
282. MOOLENAAR, W. H., KRUIJER, W., TILLY, B. C., VERLAAN, I., BURMAN, A. J., AND DELAAT, S. W.: Growth factor-like activity of phosphatidic acid. Nature (Lond.) 323: 171-173, 1986.
283. MORISHITA, R., GIBBONS, G. H., PRATT, R. E., TOMITA, N., KANEDA, Y., OGIHARA, T., ET AL.: Autocrine and paracrine effects of atrial natriuretic peptide gene transfer on vascular smooth muscle cells and endothelial cellular growth. J. Clin. Invest. 94: 824-829, 1994.
284. MULDER, M., LOMBARDI, P., JANSEN, H., VAN BERKEL, T. J. C., FRANTS, R. R., AND HAVEKES, L. M.: Low density lipoprotein receptor internalizes low density and very low density lipoproteins that are bound to heparan sulfate proteoglycans via lipoprotein lipase. J. Biol. Chem. 268: 9369-9375, 1993.
285. MURAMATSU, M., IWAMA, Y., SHIMIZU, K., ASANO, H., TOKI, Y., MIYAZAKI, Y., ET AL.: Hypoxia-elicited contraction of aorta and coronary arteries via removal of endothelial-derived nitric oxide. Am. J. Physiol. 263: H1339-H1347, 1992.
286. MURATA, K., AND YOKOYAMA, T.: Acidic glycosaminoglycans, lipid and water contents in human coronary arterial branches. Atherosclerosis. 45: 53-65, 1982.
287. MURATA, K., AND YOKOYAMA, Y.: Acidic glycosaminoglycans in human cerebral arterial tissues. Atherosclerosis. 78: 67-79, 1989.
288. 3 levels with the risk of myocardial infarction. Am. J. Med. 98: 357-364, 1995.
289. NABEL, E. G., SELWYN, A. P., AND GANZ, P.: Large coronary arteries in humans are responsive to changing blood flow: a mechanism that fails in atherosclerosis. J. Am. Coll. Cardiol. 16: 349-356, 1990.
290. NACHMAN, R. L.: Thrombosis and atherogenesis: molecular connections. Blood. 79: 1897-1906, 1992.
291. NATHAN, C.: Nitric oxide as a secretory product of mammalian cells. FASEB J. 6: 3051-3064, 1992.
292. NELSON, R. M., CECCIONI, D., ROBERTS, W. G., ARUFFO, A., LINDHARDT, R. J., AND BEVILACQUA, M. P.: Heparin oligosaccharides bind L- and P-selectins and inhibit acute inflammation. Blood. 82: 3253-3258, 1993a.
293. NELSON, S., JESKE, W., HOPPENSTAEDT, D., AND FAREED, J.: Tissue factor inhibitor release after the administration of low molecular weight heparin and synthetic sulfated agents (abstract). FASEB J. 7: 1211, 1993b.
294. NEYTA, J., SNOECK, R., SCHOLS, D., BALZARINI, J., ESKO, J. D., SHEPDAEL, A. V., AND DECLERQ, E.: Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparan sulfate. Virology. 189: 48-58, 1992.
295. NIKKILA, M., SOLAKINI, T., LEHTIMAKI, T., KOIVULA, T., LAIPPALA, T., AND ASTROM, B.: Postprandial plasma lipoprotein changes in relation to Apo E phenotype and LDL size in men with and without coronary artery disease. Atherosclerosis. 106: 149-157, 1994.
296. NILLSON, U. A., HARALDSSON, G., BRATELL, S., SORENSON, V., AKERLUND, S., PETTERSON, S., SCHERSTEN, I., AND JONSSON, O.: ESR measurement of oxygen radicals in vivo after renal ischemia: effects of pretreatment with superoxide dismutase and heparin. Acta Physiol. Scand. 147: 263-270, 1993.
297. NISHINAGA, M.: Heparan sulfate of proteoglycans of endothelial cells: homocysteine suppresses anticoagulant active heparan sulfate in cultured endothelial cells. Medicus, English Abat., August: 635, 1994.
298. NISHINAGA, M., OZAWA, T., AND SHIMADA, K.: Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J. Clin. Invest. 92: 1381-1386, 1993.
299. NODA, K., SASAGURI, M., IDEISHI, M., IKEDA, M., AND ARAKAWA, K.: Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc. Res. 27: 334-340, 1993.
300. NORGARD-SUNNICHT, K. E., VARKI, N. M., AND VARKI, A.: Calcium-dependent heparin-like ligands for L-selectin in nonlymphoid endothelial cells. Science (Wash. DC) 261: 480-483, 1993.
301. NUMER, G. L., THOMAS, C. N., HANSON, S. R., BARRY, J. J., KING, S. B., AND SCOTT, N. A.: Inhibition of platelet-dependent thrombosis by local delivery of heparin with a hydrogel-coated balloon. Circulation. 92: 1697-1700, 1995.
302. O'BRIEN, E. R., GARVIN, M. R., STEWART, D. K., HINOHARA, T., SIMPSON, J. B., SCHWARTZ, S. M., ET AL.: Osteopontin is synthesized by macrophages, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler. Thromb. 14: 1648-1656, 1994.
303. OKAZAKI, M., HU, Z. W., FUJINAGA, M., AND HOFFMAN, B. B.: Alpha 1 adrenergic receptor-induced c-fos gene expression in rat aorta and cultured vascular smooth muscle cells. J. Clin. Invest. 94: 210-218, 1994.
304. OKAZAKI, M., MAJESKY, M. W., HARKER, L. A., AND SCHWARTZ, S. M.: Regulation of PDGF ligand and receptor gene expression by alpha thrombin in vascular smooth muscle cells. Arterioscler. Thromb. 12: 1099-1109, 1992.
305. OPPENHEIM, J. S., ZACHARIAE, C. D. C., MUKAIDA, M., AND MATSUSHIMA, K.: Properties of the novel pro-inflammatory supergene intercrine cytokine family. Annu. Rev. Immunol. 9: 617-648, 1991.
306. ORLANDI, A., ROPRAZ, P., AND GABBIANI, G.: Proliferative activity and alpha-SM actin expression in cultured rat aortic smooth muscle cells are differently modulated by TGF-B1 and heparin. Exp. Cell Res. 214: 528-536, 1994.
307. ORLIDGE, A., AND D'AMORE, P. A.: Cell specific effects of glycosaminoglycans on the attachment and proliferation of vascular wall components. Microvasc. Res. 31: 41-53, 1986.
308. OTTLINGER, M. E., PUKAC, L. A., AND KARNOVSKY, M. J.: Heparin inhibits mitogen-activated protein kinase in rat vascular smooth muscle cells. J. Biol. Chem. 268: 19173-19176, 1993.
309. PATSCH, J. R.: Triglyceride-rich lipoproteins and atherosclerosis. Atherosclerosis. 110(suppl.): 523-526, 1994.
310. PATSCH, J. R., MIESENBOCK, G., HOPPERWIESER, T., MUHLBERGER, V., KNAPP, E., DUNN, J. K., ET AL.: Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler. Thromb. 12: 1336-1345, 1992.
311. PAULY, R. M., BILATO, C., SOLLOTT, S. J., MONTICONE, R., KELLY, P. T., LAKATTA, E. G., AND CROW, M. T.: The role of calcium/calmodulin-dependent protein kinase II in the regulation of vascular smooth muscle cell migration. Circulation. 91: 1107-1115, 1995.
312. PELECH, S. L., AND SANGHERA, J. S.: Mitogen activated protein kinases: charting the regulatory pathways. Science (Wash. DC) 257: 1355-1356, 1992.
313. PETERSEN, L. C., BJORN, S. E., AND NORDFANG, O.: Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb. Haemostasis. 67: 537-541, 1992.
314. PHAIR, R. D.: Cellular calcium and atherosclerosis: a brief review. Cell Calcium. 9: 275-284, 1988.
315. PIMSTONE, S. N., GAGNE, S. E., GAGNE, C., LUPIEN, P., GAUDET, D., AND WILLIAMS, R.: Mutations in the gene for lipoprotein lipase: a cause for low HDL cholesterol levels in individuals heterozygous for familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 15: 1704-1712, 1995.
316. PINHAL, M. A. S., WALENGA, J. M., JESKE, W., AND FAREED, J.: Antithrombotic agents stimulate the synthesis and modify the sulfation pattern of a heparan sulfate proteoglycan from endothelial cells. Thromb. Res. 74: 143-153, 1994.
317. PIZCUETA, P., AND LUSCINSKAS, F. W.: Monoclonal antibody blockade of L-selectin inhibits mononuclear leukocyte recruitment to inflammatory sites in vivo. Am. J. Pathol. 145: 461-469, 1994.
318. PLATT, J. L., VERCELLOTTI, G. M., LINDMAN, B. L., OEGEMA, JR., T. R., BACH, F. H., AND DALMASSO, A. P.: Release of heparan sulfate from endothelial cells: implications for pathogenesis of hyperacute rejection. J. Exp. Med. 171: 1363-1368, 1990.
319. QUYYAMI, A. A., DOKAK, N., ANDREWS, N. P., HUSAIN, S., ARORA, S., GILLINGER, D. M., ET AL.: Nitric oxide activity in the human coronary circulation. J. Clin. Invest. 95: 1747-1755, 1995.
320. RABBANI, L. E., AND LOSCALZO, J.: Recent observations on the role of hemostatic determinants in the development of atherothrombotic plaque. Atherosclerosis. 105: 1-7, 1994.
321. RADHAKRISHNAMURTHY, B., RUIZ, H. A., DALFERES, JR., E. R., SRINIVASAN, S. R., FOSTER, T. A., AND BERENSON, G. S.: Studies of arterial wall glycosaminoglycans and collagen during experimental regressions of atherosclerotic lesions in cynomolgous monkeys. Lab. Invest. 47: 153-159, 1982.
322. RADHAKRISHNAMURTHY, B., SRINIVASEN, S. R., VIJAYAGOPAL, A., AND BERENSON, G. S.: Arterial wall proteoglycans: biologic properties related to pathogenesis of atherosclerosis. Eur. Heart J. 11(suppl. E): 148-157, 1990.
323. RANUCCI, M., REANTRAGOON, S., ARRIGO, L. M., SCOUD, M. M., DWECK, H. S., AND ROSENFELD, L.: Specific heparin fractions suppress endothelin-1 production in cultured human umbilical vein endothelial cells. Arch. Biochem. Biophys. 314: 315-322, 1994.
324. RAO, G. N., AND BERK, B. C.: Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ. Res. 70: 593-599, 1992.
325. REDINI, F., TIXIER, J. M., PETITOU, M., CHOAY, J., ROBERT, L., AND HORNEBECK, W.: Inhibition of leukocyte elastase by heparin and its derivatives. Biochem. J. 252: 515-519, 1988.
326. REIDY, M. A., AND BOWYER, D.: Control of smooth muscle cell proliferation. Curr. Opin. Lipidol. 4: 349-354, 1993.
327. REINARTZ, J., HANSCH, G. M., AND KRAMER, M. D.: Complement component C7 is a plasminogen-binding protein. J. Immunol. 154: 844-850, 1995.
328. RICE, G. C., BROWN, P. A., NELSON, R. J., BIANCO, J. A., SINGER, J. W., AND BURSTEN, S.: Protection from endotoxin shock in mice by pharmacologic inhibition of phosphatidic acid. Proc. Natl. Acad. Sci. USA 91: 3857-3861, 1994.
329. ROBERTSON, JR., A. L., KATSURA, Y., AND STEIN, R. J.: Viral genomes and arterial disease. Ann. N.Y. Acad. Sci. 748: 57-73, 1995.
330. ROLLINS, B. J., YOSHIMURA, T., LEONARD, E. J., AND POBER, J. S.: Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1. Am. J. Pathol. 136: 1229-1233, 1990.
331. ROSEN, E. M., KNESEL, J., AND GOLDBERG, I. D.: Scatter factor and its relationship to hepatocyte growth factor and metastasis. Cell Growth Diff. 2: 603-607, 1991.
332. ROSENBERG, R. D.: Vascular smooth muscle cell proliferation: basic investigations and new therapeutic approaches. Thromb. Haemostasis. 70: 10-16, 1993.
333. ROSS, M. A., LONG, W. F., AND WILLIAMSON, F. B.: Inhibition by heparin of Fe-catalyzed free radical peroxidation of linolenic acid. Biochem. J. 286: 717-720, 1992.
334. ROSS, R.: The pathogenesis of atherosclerosis: an update. New Eng. J. Med. 314: 488-500, 1986.
335. ROSS, R.: The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature (Lond.) 362: 801-809, 1993.
336. RUOSLAHTI, E.: Structure and biology of proteoglycans. Annu. Rev. Cell Biol. 4: 229-255, 1988.
337. RYAN, U. S.: Complement inhibitory therapeutics and xenotransplantation. Nature Med. 1: 967-968, 1995.
338. SAADI, S., AND PLATT, J. L.: Transient perturbation of endothelial integrity induced by natural antibodies and complement. J. Exp. Med. 181: 21-31, 1995.
339. SABU, A., AND PANGBORN, N. K.: Identification of multiple sites of interaction between heparin and the complement system. Mol. Immunol. 30: 670-684, 1993.
340. 3 synthesis in immune complex nephritis. Lancet. 342: 1273-1274, 1993.
341. SALOMAA, V., STINSON, V., KARK, D., FOLSOM, A. R., DAVIS, C. E., AND WU, K. K.: Association of fibrinolytic parameters with early atherosclerosis: ARIC study. Circulation. 91: 284-290, 1995.
342. SASAGURI, Y., MURAHASHI, N., SUGAMA, K., KATO, S., HIRAOKA, K., SATOH, T., ISOMOTO, H., AND MORIMATSU, M.: Development-related changes in matrix metalloprotease expression in human aortic smooth muscle cells. Lab. Invest. 71: 261-269, 1994.
343. SASAKI, A., SEVARAN, P., AND GOLDBERG, I. J.: Lipoprotein lipase binding to adipocytes: evidence for the presence of a heparin-sensitive binding protein. Am. J. Physiol. 265: E880-E888, 1993a.
344. SASAKI, M., HERD, C. M., AND PAGE, C. P.: Effect of heparin on platelet active factor-induced airway responses in neonatally immunized rabbits. Br. J. Pharmacol. 110: 107-112, 1993b.
345. SAVAGE, C. O. S., POTTINGER, B. E., GASKIN, G., PUSEY, C. D., AND PEARSON, J. D.: Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am. J. Pathol. 141: 335-342, 1992.
346. SAXENA, V., KLEIN, M. G., AND GOLDBERG, I. G.: Transport of lipoprotein lipase across endothelial cells. Proc. Natl. Acad. Sci. USA 88: 2254-2258, 1991.
347. SCHIFFERLI, J. A., NG, Y. C., AND PETERS, D. K.: The role of complement and its receptor in the elimination of immune complexes. New Eng. J. Med. 315: 488-495, 1986.
348. SCHILLING, P., FISCHER, H., AND GANTEN, D.: Angiotensin and cell growth: a link to cardiac and vascular hypertrophy. J. Hypertension. 9: 3-15, 1991.
349. SCHINI, V. B., CATOVSKY, S., DURANTE, W., SCOTT-BURDEN, T., SCHAFER, A. I., AND VANHOUTTE, P. M.: Thrombin inhibits production of nitric oxide synthase in vascular smooth muscle cells. Am. J. Physiol. 264: H611-H616, 1993.
350. SCHMIDT, A. M., HORI, O., BRETT, J., YAU, S. D., WAUTIER, J. L., AND STERN, D.: Cellular receptors for advanced glycosylation end-products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscl. Thromb. 14: 1521-1528, 1994.
351. SCHMIDT, A. M., HORI, D., CHEN, J. X., LI, J. F., CRANDALL, J., ZHANG, J., ET AL.: Advanced glycosylation end products interacting with their endothelial receptor induce expression of VCAM-1 in cultured endothelial cells in mice: potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 96: 1395-1403, 1995.
352. SCHRACK, R., MEIER, B., MANNUCK, D. N., DROGE, W., AND BAUERLE, P. A.: Dithiocarbonates as potent inhibitors of NF-kB in intact cells. J. Exp. Med. 175: 1181-1184, 1992.
353. SCHRACK, R., RIEBER, P., AND BAUERLE, P. A.: Reactive oxygen
354. SCHWARTZ, C. J., VALENTE, A. J., KELLEY, J. L., SPRAGUE, E. A., AND EDWARDS, E. H.: Thrombosis and the development of atherosclerosis: Rokitansky revisited. Semin. Thromb. Hemost. 14: 89-95, 1988.
355. SCHWARTZ, C. J., VALENTE, A. J., SPRAGUE, E. A., KELLEY, J. L., AND NEREM, R. M.: The pathogenesis of atherosclerosis: an overview. Clin. Cardiol. 14: 11-16, 1991.
356. SCHWARTZ, D., ANDOLIBI, A., AND CHAVERRI-ALMADA, L.: Role of the GRO family of chemokines in monocyte adhesion to MM-LDL-stimulated endothelium. J. Clin. Invest. 94: 1968-1973, 1994.
357. SCHWARTZ, S. M., DEBLOIS, D., AND O'BRIEN, E. R. M.: The intima: soil for atherosclerosis and restenosis. Circ. Res. 77: 445-463, 1995a.
358. SCHWARTZ S. M., REIDY, M. A., O'BRIEN, E. R. M.: Assessment of factors important in atherosclerotic occlusion and restenosis. Thromb. Hemost. 74: 541-551, 1995b.
359. SEEDS, E. A., HANAS, J. I., AND PAGE, C. P.: The effect of heparin and related proteoglycans on allergen and PAF-induced eosinophilic infiltration. J. Lipid Mediat. 7: 269-278, 1993.
360. SEIFERT, P. S., AND KATZATCHKINE, M. D.: The complement system in atherosclerosis. Atherosclerosis. 73: 91-104, 1988.
361. 3 activation products in human atherosclerotic lesions. Atheroscler. 91: 155-162, 1991.
362. SHATS-TSETYLINA, E. A., NAIR, C. H., AND DAHL, D. P.: Complement activation: a new participant in the modulation of fibrin gel characteristics and the progression of atherosclerosis. Blood Coag. Fibrinol. 5: 529-535, 1994.
363. SHI, Y., FARD, A., GALEO, A., HUTCHINSON, H., VERMANI, P., DODGE, G., ET AL.: Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation. 90: 944-951, 1994.
364. SHI, Y., HUTCHINSON, H. G., HALL, O. J., AND ZALEWSKI, A.: Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells. Circulation. 88: 1190-1195, 1993.
365. SHIMADA, M., ISHIBASHI, S., GOTODA, T., KAWAMURA, M., YAMAMOTO, K., INABA, T., ET AL.: Overexpression of human lipoprotein lipase protects diabetic transgenic mice from diabetic hypertriglyceridemia and hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 15: 1688-1694, 1994.
366. SHIMADA, M., SHIMANO, H., GOTOTADA, T., YAMAMOTO, K., KAWAMURA, M., INABA, T., ET AL.: Overexpression of human lipoprotein lipase in transgenic mice: resistance to diet-induced hypertriglyceridemia and hypercholesterolemia. J. Biol. Chem. 268: 17924-17929, 1993.
367. SHREENIEVAS, R., KOGA, S., KARKURUM, M., PINSKY, D., KAISER, E., BRETT, J., WOLITZKY, B. A., NORTON, C., PLOCINSKI, J., BENJAMIN, W., BURNS, D. K., GOLDSTEIN, A., AND STERN, D.: Hypoxia-mediated induction of endothelial cell IL-1: an autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface. J. Clin. Invest. 90: 2333-2339, 1992.
368. SIESJO, B. K.: Calcium-mediated processes in neuronal degeneration. Ann. N.Y. Acad. Sci. 747: 140-161, 1994.
369. SILVESTRO, L., RUIKUN, C., SOMMER, F., DUC, T. M., BIANCOME, L., MONTRUCCHIO, G., AND CAMUSSI, G.: Platelet activating factor-induced expression of adhesion molecules and modulation of surface glycocalyx, evaluated by electron spectroscopy chemical analysis. Semin. Thromb. Hemost. 20: 214-222, 1994.
370. SIMIONESCU, M., AND SIMIONESCU, N.: Functions of the endothelial cell surface. Annu. Rev. Physiol. 48: 279-293, 1986.
371. SIMIONESCU, M., AND SIMIONESCU, M.: Proatherosclerotic events: pathobiochemical changes occurring in the arterial wall before monocyte migration. FASEB J. 7: 1359-1366, 1993.
372. SIMONS, M., EDELMAN, E. R., AND ROSENBERG, R. D.: Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. J. Clin. Invest. 93: 2351-2356, 1994.
373. SIMONS, M., AND ROSENBERG, R. D.: Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ. Res. 70: 835-843, 1992.
374. SIMONSON, M. B.: Endothelins: multifunctional renal peptides. Physiol. Rev. 73: 375-402, 1993.
375. SMITH, C., MITCHINSON, J. M., ARUOMA, O. I., AND HALLIWELL, B.: Stimulation of lipid peroxidation and hydroxyl radical generation by the contents of human atherosclerotic lesions. Biochem. J. 286: 901-905, 1992.
376. SOKER, S., GOLDSTAUB, D., SVAHU, C. M., VLODAVSKY, I., LEVI, B.-Z., AND NEUFELD, G.: Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF to its receptor. Biochem. Biophys. Res. Commun. 203: 1339-1347, 1994.
377. SOMLYO, A. P., AND SOMLYO, A. V.: Signal transduction and regulation in smooth muscle. Nature (Lond.) 372: 231-236, 1994.
378. SPAN, A. H. M., GRASSELS, G., BOSMAN, F., VAN BOVEN, C. P. A., AND BRUGGEMAN, C. A.: Cytomegalovirus infection induces vascular injury in the rat. Atherosclerosis. 93: 41-52, 1992.
379. SPEIR, E., MODALI, R., HUANG, E-S., LEON, M., SHAWL, F., FINKEL, T., ET AL.: Potential role of human cytomegalous virus and p53 interaction in human coronary restenosis. Science (Wash. DC) 265: 391-394, 1994.
380. SPORN, M. B., AND ROBERTS, A. B.: Transforming growth factor-B: recent progress and new challenges. J. Cell Biol. 119: 1017-1021, 1992.
381. SPRAGUE, E. A., MOSER, M., EDWARDS, E. H., AND SCHWARTZ, C. J.: Stimulation of receptor-mediated low density lipoprotein endocytosis in neuraminidase-treated cultured bovine aortic endothelial cells. J. Cell. Physiol. 137: 251-262, 1988.
382. SPRINGER, T. A.: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 76: 301-314, 1994.
383. STAHL, G. L., REENSTRA, W. R., AND FRENDL, G.: Complement-mediated loss of endothelial-dependent relaxation of porcine coronary arteries: role of the terminal membrane attack complex. Circ. Res. 76: 575-583, 1995.
384. STAMLER, J. S., LOH, E., RODDY, M-A., CURRIE, K. E., AND CRAEGER, M. A.: Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation. 89: 2035-2040, 1994.
385. STAMLER, J. S., OSBORNE, J. A., JARAKI, O., RABBANI, L. E., MULLINS, M., SINGEL, D., AND LOSCALZO, J.: Adverse vascular effects of homocysteine are modulated by endothelial-derived relaxing factor and related oxides of nitrogen. J. Clin. Invest. 91: 308-318, 1993.
386. STANLEY, P.: Glycosylation mutants of animal cells. Annu. Rev. Genet. 18: 525-552, 1984.
387. 2 generation from homocysteine. J. Clin. Invest. 77: 1370-1376, 1986.
388. STARKEY, P. M., AND BARRETT, A. J.: Human catepsin G: catalytic and immunological properties. Biochem. J. 155: 273-278, 1976.
389. STARY, H. C., CHANDLER, A. B., GLAGOV, S., GUYTON, J. R., INSULL, JR., W., ROSENFELD, M. E., SCHAFFER, S. A., SCHWARTZ, C. J., WAGNER, W. D., AND WISSLER, R. W.: A definition of the initial fatty streak and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions, Council on Arteriosclerosis, American Heart Association. Circulation 85: 391-405, 1992.
390. STEELE, R. H., WAGNER, W. D., ROWE, H. A., AND EDWARDS, R. J.: Artery wall derived proteoglycan-plasma lipoprotein interaction: lipoprotein binding properties of extracted proteoglycans. Atherosclerosis. 65: 51-62, 1987.
391. STEIN, Y., AND GOTTO, JR., A. M.: A symposium: triglycerides as a vascular risk factor: a global forum. Am. J. Cardiol. 70(suppl.): 1H-31H, 1992.
392. STEMERMAN, M. B.: Hemostasis, thrombosis and atherogenesis. Atheroscler. Rev. 6: 105-146, 1979.
393. STETLER-STEVENSON, W. G., LIOTTA, L. A., AND KLEINER, D. E.: Extracellular matrix 6: role of matrix metalloproteases in tumor invasion and metastasis. FASEB J. 7: 1434-1441, 1993.
394. STEVENSON, F. T., BURSTEN, S. L., FANTON, C., LOCKSLEY, R. M., AND LOVETT, D. H.: The 31k-Da precursor of interleukin-1a is myristolated on specific lysines within the 16-kDa N-terminal propiece. Proc. Natl. Acad. Sci. USA 90: 7245-7249, 1993.
395. STEVENSON, F. T., BURSTEN, S. L., LOCKSLEY, R. M., AND LOVETT, D. H.: Myristyl acylation of the tumor necrosis factor-a precursor on specific lysine residues. J. Exp. Med. 176: 1053-1062, 1992.
396. STIKO-RAHN, A., HULTZARDH-NILSSON, A., REGENSTROM, J., HAMSTEN, A., AND NILSSON, J.: Native and oxidized LDL enhance production of PDGF-AA and the surface expression of PDGF receptors in cultured human smooth muscle cells. Arterioscler. Thromb. 12: 1099-1109, 1992.
397. SUZIE, D., MANDEL, A. K., RADUYKOVIC, G., VASOLIC, D., AND KENTERA, D.: Prostaglandin synthesis inhibitors potentiate the antihypertensive effects of heparin in spontaneously hypertensive rats. J. Lab. Clin. Med. 111: 63-72, 1988.
398. SWANSON, J. A., AND KERN, D. F.: Characterization of pulmonary endothelial charge barriers. Am. J. Physiol. 266: H1300-H1303, 1994.
399. SYLVESTRE, D. L., AND RAVITCH, J. V.: Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science (Wash. DC) 265: 1095-1098, 1994.
400. TAKAGISHI, T., SASAGURI, Y., NAKANO, R., ARIMA, M., TAMIMOTO, A., FUKURI, H., ET AL.: Expression of the histamine H-1 receptor gene in relation to atherosclerosis. Am. J. Pathol. 146: 981-988, 1995.
401. TANGELDER, G. F., AND ARFORS, K. E.: Inhibition of leukocyte rolling in venules by sulfated polysaccharides. Fed. Proc. 46: 1542, 1987.
402. TANNER, F. C., BOULANGER, C. M., AND LUSCHER, T. F.: Endothelial-derived nitric oxide, endothelin, and platelet vessel wall interaction: alterations in hypercholesterolemia and atherosclerosis. Sem. Thromb. Hemost. 19: 167-175, 1993.
403. TANNER, F. C., NOLL, G., BOULANGER, C. M., AND LUSCHER, T. F.: Oxidized low density lipoproteins inhibit relaxation of porcine coronary arteries: role of scavenger receptor and endothelium-derived nitric oxide. Circulation. 83: 2012-2020, 1991.
404. TEMIZER, D. H., YOSHIZUMI, M., PERELLA, M. A., SUZANN, E. E., QUERTERMOUS, T., AND LEE, M. E.: Induction of heparin-binding epidermal growth factor-like growth factor m RNA by phorbol ester and angiotensin II in rat aortic smooth muscle cells. JBC 267: 24892-24896, 1992.
405. TERRES, W., TATSIS, E., PFALZER, B., BEIL, F. U., BIESIEZEL, V., AND HAMM, C. W.: Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein a. Circulation. 91: 948-950, 1995.
406. THORN, J. A., CHAMBERLAIN, J. C., ALCOLADO, J. C., OKA, K., CHAN, L., STOCKS, J., AND GALTON, D. J.: Lipoprotein and hepatic lipase gene variants in coronary atherosclerosis. Atherosclerosis. 85: 55-60, 1990.
407. THYBERG, J., HEDIN, V., SJOLUND, M., PALMBERG, L., AND BOTTGER, B. A.: Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis. 10: 966-990, 1990.
408. TINA-AU, Y. P., KENAGY, R. D., CLOWES, M. W., AND CLOWES, A.: Mechanisms of inhibition by heparin of vascular smooth muscle cell proliferation and migration. Haemostasis. 23(suppl. 1): 177-182, 1993.
409. TIPPING, P. G., AND HANCOCK, W. W.: Production of tumor necrosis factor and interleukin-1 by macrophages from human atherosclerotic plaques. Am. J. Pathol. 142: 1721-1728, 1993.
410. TRITSCHLER, H-J., AND MEDORI, R.: Mitochondrial DNA alterations as a source of human disorders. Neurology. 43: 280-288, 1993.
411. TRYBALA, E., SVENNERHOLM, B., BERGSTROM, T., OLOFSSON, S., JEANSSON, S., AND GOODMAN, J. L.: HSV-1-induced hemagglutination: glycoprotein c mediates virus binding to erythrocyte surface heparan sulfate. J. Virology. 67: 1278-1285, 1993.
412. TSAI, J-C., PERRELLA, M. A., YOSHIZUMI, M., HSICH, C-M., HABER, E., SCHLEGEL, R., AND LEE, M. E.: Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc. Natl. Acad. Sci. USA 91: 6369-6373, 1994.
413. TSUTSUMI, K., INOYE, Y., SHIMA, A., IWASAKI, K., KAWAMURA, M., AND MURASE, T.: The novel compound NO-1886 increases lipoprotein lipase activity with resultant elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. J. Clin. Invest. 92: 411-417, 1993.
414. UITERWAAL, C. S. P. M., GROBER, D. E., WITTERMAN, J. C. M., VAN STIPHONT, W. A. S., KRAUSS, X. H., ET AL.: Postprandial triglyceride response in young adult men and familial risk for coronary atherosclerosis. Ann. Int. Med. 121: 576-583, 1994.
415. VANNIER, C., AND AILHAUD, G.: Biosynthesis of lipoprotein lipase in cultured mouse adipocytes II; processing, subunit assembly, and intracellular transport. J. Biol. Chem. 264: 13206-13216, 1989.
416. VARKI, A.: Biological roles of oligosaccharides: all of the theories are correct. Glycobiology. 3: 97-130, 1993.
417. VAUGHN, D. E., LAZOS, S. A., AND TONG, K.: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J. Clin. Invest. 95: 995-1001, 1995.
418. VERCELLOTTI, G. M.: Proinflammatory and procoagulant effects of herpes simplex infection on human endothelium. Blood Cells. 16: 209-216, 1990.
419. VIJAYAGOPOL, P.: Enhanced synthesis and accumulation of proteoglycans in cholesterol-enriched arterial smooth muscle cells. Biochem. J. 294: 603-611, 1993.
420. VITA, J. A., TREASUR, C. B., NABEL, E. G., MCLENACHAN, J. M., FISH, D., YOUNG, A. C., VEKSHTEIN, V. I., SELWYN, A. P., AND GANZ, P.: Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 81: 491-497, 1990.
421. VLASSARA, H.: Recent progress on the biologic and clinical significance of advanced glycosylation end-products. J. Lab. Clin. Med. 124: 19-30, 1994.
422. VLODAVSKY, I., MIAO, H-Q., ATZMON, R., LEVI, E., ZIMMERMAN, J., BAR-SHAVIT, R., ET AL.: Control of cell proliferation by heparan sulfate and heparin-binding growth factors. Thromb. Haemostasis. 74: 534-540, 1995.
423. VOLKER, W., SCHMIDT, A., OORTMAN, W., BROSZEY, T., FABER, V., AND BUDDECKE, E.: Mapping of proteoglycans in atherosclerotic lesions. Eur. Heart J. 11(suppl. E): 29-40, 1990.
424. VOLKIN, D. B., TSAI, P. K., DABORA, J. M., GRESS, J. O., BURKE, C. J., LINHARDT, R. J., AND MIDDAUGH, C. R.: Physical stabilization of acidic fibroblast growth factor by polyanions. Arch. Biochem. Biophys. 300: 30-41, 1993.
425. VOLPI, N., CUSMANO, M., AND VENTURELLI, T.: Qualitative and quantitative studies of heparin and chondroitin sulfates in normal human plasma. Biochim. Biophys. Acta. 1243: 49-58, 1995.
426. WARD, B. J., AND DONNELLY, J. L.: Hypoxia induced disruption of the cardiac endothelial glycocalyx: implications for capillary permeability. Cardiovasc. Res. 27: 384-389, 1993.
427. WARD, P. A.: Mechanisms of endothelial cell injury. J. Lab. Clin. Med. 118: 421-426, 1991.
428. WARD, P. A., WARREN, J. S., VARANI, J., AND JOHNSON, K. J.: PAF, cytokines, toxic oxygen products and cell injury. Mol. Aspects Med. 12: 169-174, 1991.
429. WARREN, J. S., MANDEL, D. M., JOHNSON, K. J., AND WARD, P. A.: Evidence for the role of platelet activating factor in immune complex vasculitis in the rat. J. Clin. Inves. 83: 669-678, 1989.
430. WATSCHINGER, B., SAYEGH, M. H., HANCOCK, W. W., AND RUSSELL, M. E.: Upregulation of endothelin-1 mRNA and peptide expression in rat cardiac allografts with rejection and atherosclerosis. Am. J. Pathol. 146: 1065-1072, 1995.
431. WEGROWSKI, J., MOCZAR, M., AND ROBERT, L.: Proteoglycans from pig aorta: comparative study of their interactions with lipoproteins. Biochem. J. 235: 823-831, 1986.
432. WEILER, J. M., EDENS, R. E., LINHARDT, R. J., AND KAPELANSKI, D. P.: Heparin and modified heparin inhibit complement activation in vivo. J. Immunol. 148: 3210-3215, 1992.
433. WEINTRAUB, M. E., EISENBERG, S., AND BRESLOW, J. L.: Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III and type IV hyperlipoproteinemic individuals. J. Clin. Invest. 79: 1110-1119, 1987.
434. WEINTRAUB, M., RINGEL, Y., RASSIN, T., ARAD, J., BODNER, G., AND LIRON, M.: Octogenarian subjects have low postprandial levels of chylomicron remnants: a possible explanation for protection against atherosclerosis. J. Gerontol. 47: B209-B213, 1992.
435. WEISS, S. J.: Tissue destruction by neutrophils. New Eng. J. Med. 320: 365-376, 1989.
436. WEISSER, B., LOCHER, R., MANGDEN, T., AND VETTER, W.: Oxidation of LDL and its potential to increase intracellular free calcium concentration in vascular smooth muscle cells. Arterioscler. Thromb. 12: 231-236, 1992.
437. WENNHALM, A.: Endothelial nitric oxide and cardiovascular disease. J. Int. Med. 235: 317-327, 1994.
438. WEYRICK, A. S., MCINTYRE, T. M., MCEVER, R. P., AND ZIMMERMAN, G. A.: Monocyte tethering by P-selectin regulates MCP-1 and TNF-a secretion. J. Clin. Invest. 95: 2297-2303, 1995.
439. WIEDERMAN, C. J., KOWALD, E., AND REINISCH, N.: Monocyte haptotaxis induced by the RANTES chemokine. Curr. Biol. 3: 735-739, 1993.
440. WIEMER, G., SCHOLKENS, B. A., AND LINZ, W.: Endothelial protection by converting enzyme inhibitors. Cardiovasc. Res. 28: 166-172, 1994.
441. WIEZOREK, J. S., BROWN, D. H., KUPPERMAN, D. E., AND BRASS, C. E.: Rapid conversion to high xanthine oxidase activity in viable Kupfer cells during hypoxia. J. Clin. Invest. 94: 2224-2230, 1994.
442. WIGHT, T. N.: Cell biology of arterial proteoglycans. Arteriosclerosis. 9: 1-20, 1989.
443. WIGHT, T. N., POTTER-PERIGO, S., AND AULINSKAS, T.: Proteoglycans and vascular cell proliferation. Am. Rev. Resp. Dis. 140: 1132-1135, 1989.
444. WILLIAMS, S. P., AND MASON, R. M.: Modulation of proteoglycan synthesis by bovine vascular smooth muscle cells during cellular proliferation and treatment with heparin. Arch. Biochem. Biophys. 287: 386-396, 1991.
445. WILSON, D. E., EMI, M., IVERIUS, P-H., HATA, A., WU, L. L., HILLAS, A., WILLIAMS, R. R., AND LALOUEL, J-M.: Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missence mutation. J. Clin. Invest. 86: 735-750, 1990.
446. WITZTUN, J. L.: The oxidation hypothesis of atherosclerosis. Lancet. 344: 793-795, 1994.
447. WITZTUN, J. L., AND STEINBERG, D.: Role of oxidized LDL in atherogenesis. J. Clin. Invest. 88: 1785-1792, 1991.
448. WRIGHT, T. M., WILLENBERGER, S., AND RABEN, D. M.: Activation of phospholipase D by a-thrombin or epidermal growth factor contributes to the formation of phosphatidic acid but not to increases of 1-2-diacylglycerol. Biochem. J. 285: 394-400, 1992.
449. WU, H. F., LUNDBLAD, R. L., AND CHURCH, F. C.: Neutralization of heparin activity by lactoferrin. Blood. 85: 421-428, 1995.
450. YAMAMOTO, T., AND WILSON, C. B.: Complement dependence of antibody-induced mesangial cell injury in the rat. J. Immunol. 138: 3758-3765, 1987.
451. YAN, S. D., SCHMIDT, A. M., ANDERSON, G. M., ZHANG, J., BRETT, J., ZOU, Y., ET AL.: Enhanced cellular oxidant stress by the interaction of advanced glycosylation end products with their receptor-binding proteins. J. Biol. Chem. 269: 9889-9897, 1994.
452. YLA-HERTUALLA, S., SUMUVEROSI, H., KARKOLA, K., MOTTONEN, M., AND NIKKARI, T.: Glycosaminoglycans in normal and atherosclerotic human coronary arteries. Lab. Invest. 54: 402-407, 1986.
453. YOKOKAWA, K., KOHNO, M., TAHARA, H., ET AL.: Effect of heparin on endothelin-1 production by cultured human endothelial cells. J. Cardiovasc. Pharmacol. 22(suppl. 8): 546-548, 1993a.
454. YOKOKAWA, K., MANDAL, A. K., KOHNO, M., HORIO, T., MURAKAWA, K-I., YASUNARI, K., AND TAKEDA, T.: Heparin suppresses endothelin-1 action and production in spontaneously hypertensive rats. Am. J. Physiol. 263: R1035-R1041, 1992.
455. YOKOKAWA, K., TAKARA, H., KOHNO, M., MANDAL, A. K., YAMAGISAWA, M., AND TAKEDA, T.: Heparin regulates endothelin production through endothelial-derived nitric oxide in human endothelial cells. J. Clin. Invest. 92: 2080-2085, 1993b.
456. YU, B. P.: Cellular defenses against damage from reactive oxygen intermediates. Physiol. Rev. 74: 139-160, 1994.
457. + exchange in vascular smooth muscle cells. Am. J. Physiol. 258: C46-C53, 1990.
458. ZHU, Z., GERSHON, M. D., AMBRON, R., GABEL, C., AND GERSHON, A. A.: Infection of cells by varicella zoster virus: inhibition of viral entry by st mannose-6-phosphate and heparin. Proc. Natl. Acad. Sci. USA 92: 3546-3550, 1995.
459. ZIEHER, A. M., DREXLER, H., WOLLSCHLAGER, H., AND JUST, H.: Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation. 84: 1984-1992, 1991.
460. ZIEHER, A. M., FISSLTHALER, B., SCHRAY-UTE, B., AND BUSSE, R.: Nitric Oxide modulates the expression of monocyte chemotactic protein-1 in cultured human endothelial cells. Circ. Res. 76: 980-986, 1995a.
461. ZIEHER, A. M., GOEBEL, H., SCHACKINGER, V., AND IHLING, C.: Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque: a clue to the mechanism of the culprit lesion in unstable angina. Circulation. 91: 941-947, 1995b.
462. 2 activation. Biochem. J. 295: 879-888, 1993.